22nd Century (XXII) 10-K 30 Jan 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Jan. 28, 2014	Jun. 28, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'XXII	'	'
Entity Registrant Name	'22nd Century Group, Inc.	'	'
Entity Central Index Key	'0001347858	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	58,252,770	'
Entity Public Float	'	'	$18.30

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash	$5,830,599	$188
Due from related party	42,069	36,969
Due from officers	7,471	3,578
Inventory	1,406,280	1,230,526
Machinery and equipment held for resale	457,696	0
Prepaid expenses and other assets	0	10,044
Total current assets	7,744,115	1,281,305
Machinery and equipment, net	2,997,760	6,030
Other assets:	'	'
Patent and trademark costs, net	1,544,869	1,353,304
Deferred debt issuance costs, net	0	4,232
Total other assets	1,544,869	1,357,536
Total assets	12,286,744	2,644,871
Current liabilities:	'	'
Demand bank loan	174,925	174,925
Accounts payable	54,665	1,410,650
Accrued expenses	575,730	503,002
Deferred revenue	179,014	0
Accrued interest payable to related parties	0	3,567
Notes payable	0	617,000
Convertible notes, net of unamortized discount	0	1,893,804
Total current liabilities	984,334	4,602,948
Warrant liability	3,779,522	4,173,140
Total liabilities	4,763,856	8,776,088
Commitments and contingencies (Note 12)	0	0
Shareholders' equity (deficit)	'	'
Preferred shares value	0	0
Common shares value	569	344
Capital in excess of par value	47,452,055	7,645,017
Accumulated deficit	-39,929,736	-13,776,578
Total shareholders' equity (deficit)	7,522,888	-6,131,217
Total liabilities and shareholders' equity (deficit)	$12,286,744	$2,644,871

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares issued	56,902,770	34,286,979
Common stock, shares outstanding	56,902,770	34,286,979
Convertible Preferred Stock [Member]	'	'
Preferred stock, par value	$1,000	$1,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock cumulative percentage	10.00%	10.00%

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenue:	'	'
Royalties from licensing	$7,000,000	$0
Sale of products	278,383	18,775
Total Revenue	7,278,383	18,775
Cost of goods sold:	'	'
Royalties for licensing	413,566	0
Products	48,105	67,967
Total Cost of goods sold	461,671	67,967
Gross profit (loss)	6,816,712	-49,192
Operating expenses:	'	'
Research and development (including stock based compensation of $111,563 and $145,074, respectively)	744,230	729,225
General and administrative (including stock based compensation of $2,250,399 and $1,109,097, respectively)	4,106,694	2,205,450
Sales and marketing costs	9,052	61,876
Amortization and depreciation	144,289	198,406
Total operating expenses	5,004,265	3,194,957
Operating income (loss)	1,812,447	-3,244,149
Other income (expense):	'	'
Warrant liability loss - net	-23,602,711	-1,998,043
Warrant exchange inducement expense	-3,736,313	0
Income tax credit refund	122,024	0
Interest expense and amortization of debt discount and expense:	'	'
Related parties	-17,889	-272,758
Other	-730,716	-1,221,787
Total other income (expense)	-27,965,605	-3,492,588
Net loss	-26,153,158	-6,736,737
Net loss attributable to non-controlling interest	0	1,456
Net loss attributed to common shareholders	($26,153,158)	($6,735,281)
Loss per common share - basic and diluted (in dollars per share)	($0.60)	($0.22)
Common shares used in basic earnings per share calculation (in shares)	43,635,182	30,419,556

CONSOLIDATED_STATEMENTS_OF_OPE1

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Research and Development Expense [Member]	'	'
Allocated Share-based Compensation Expense	$111,563	$145,074
General and Administrative Expense [Member]	'	'
Allocated Share-based Compensation Expense	$2,250,399	$1,109,097

CONSOLIDATED_STATEMENT_OF_SHAR

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Contributed Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]
Beginning balance at Dec. 31, 2011	($1,212,160)	$0	$273	$5,822,882	($7,041,297)	$5,982
Beginning balance, shares at Dec. 31, 2011	'	0	27,209,646	'	'	'
Common stock issued upon exercise of Convertible Notes	0	0	2	-2	0	0
Common stock issued upon exercise of Convertible Notes, shares	'	0	161,000	'	'	'
Stock based compensation	722,209	0	7	722,202	0	0
Stock based compensation, shares	'	0	700,000	'	'	'
Net loss	-6,736,737	0	0	0	-6,735,281	-1,456
Common stock issued in private placement	-4,526	0	17	-17	0	-4,526
Preferred stock issued in January 2013 private placement, shares	'	0	1,710,833	'	'	'
Options granted for payment of services	10,000	0	0	10,000	0	0
Debt instrument, beneficial conversion feature	116,600	0	0	116,600	0	0
Common stock issued in private placement	455,644	0	32	455,612	0	0
Common stock issued in private placement, shares	'	0	3,238,000	'	'	'
Common stock issued as payment of services and accounts payable	517,753	0	13	517,740	0	0
Common stock issued upon exercise of Convertible Notes, shares	'	0	1,267,500	'	'	'
Ending balance at Dec. 31, 2012	-6,131,217	0	344	7,645,017	-13,776,578	0
Ending balance, shares at Dec. 31, 2012	'	0	34,286,979	'	'	'
Common stock issued upon exercise of Convertible Notes	0	0	24	-24	0	0
Common stock issued upon exercise of Convertible Notes, shares	'	0	2,406,720	'	'	'
Preferred stock issued in January 2013 private placement	0	0	4	-4	0	0
Preferred stock issued in January 2013 private placement, shares	'	2,500	416,666	'	'	'
Stock based compensation	2,361,962	0	28	2,361,934	0	0
Stock based compensation, shares	'	0	2,820,000	'	'	'
Conversion of preferred stock to common stock	0	0	42	-42	0	0
Conversion of preferred stock to common stock, shares	'	-2,500	4,166,666	'	'	'
Exercise of warrants	14,097,594	0	68	14,097,526	0	0
Exercise of warrants, shares	'	0	6,820,218	'	'	'
Exercise of options	5,200	0	0	5,200	0	0
Exercise of options, shares	'	0	20,000	'	'	'
Other contributed capital	1,660	0	0	1,660	0	0
Warrant exchange program	23,340,847	0	58	23,340,789	0	0
Warrant exchange program, shares	'	0	5,804,368	'	'	'
Common stock issued in payment of accrued dividends	0	0	1	-1	0	0
Common stock issued in payment of accrued dividends, shares	'	0	161,153	'	'	'
Net loss	-26,153,158	0	0	0	-26,153,158	0
Ending balance at Dec. 31, 2013	$7,522,888	$0	$569	$47,452,055	($39,929,736)	$0
Ending balance, shares at Dec. 31, 2013	'	0	56,902,770	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net loss	($26,153,158)	($6,736,737)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:	'	'
Amortization and depreciation	144,289	198,406
Amortization of debt issuance costs	4,232	18,173
Amortization of debt discount	134,296	1,372,018
Interest due to debt conversion	526,448	31,350
Warrant liability loss	23,602,711	1,998,043
Warrant exchange inducement expense	-3,736,313	0
Equity based employee compensation expense	980,162	807,675
Equity based payments for outside services	1,381,800	416,496
Stock issued for directors fees	0	30,000
(Increase) decrease in assets:	'	'
Inventory	-175,754	-552,403
Prepaid expenses and other assets	10,044	7,630
Increase (decrease) in liabilities:	'	'
Accounts payable	-629,101	705,415
Accrued interest payable to related parties	-3,567	-2,470
Accrued expenses	118,105	-58,041
Deferred revenue	179,014	0
Net cash provided by (used in) operating activities	3,855,834	-1,764,445
Cash flows from investing activities:	'	'
Acquisition of patents and trademarks	-290,336	-162,774
Purchase of machinery and equipment held for resale	-457,696	0
Acquisition machinery and equipment	-2,994,757	0
Net cash used by investing activities	-3,742,789	-162,774
Cash flows from financing activities:	'	'
Proceeds from issuance of notes	150,000	56,000
Payments on borrowings - notes payable	-1,620,299	-41,000
Payments on borrowings - convertible notes	-339,250	0
Net proceeds from May and November 2012 private placement	0	1,467,500
Proceeds from issuance of convertible notes	0	210,000
Net proceeds from January 2013 preferred stock private placement	2,034,664	0
Net proceeds from exercise of warrants	2,254,999	0
Net proceeds from warrant exchange program	3,239,385	0
Net proceeds from exercise of options	5,200	0
Other capital contribution	1,660	0
Net payments to related party	-5,100	-21,478
Net advances (to) from officers	-3,893	4,136
Net cash provided by financing activities	5,717,366	1,675,158
Net increase (decrease) in cash	5,830,411	-252,061
Cash - beginning of year	188	252,249
Cash - end of year	5,830,599	188
Cash paid during the year for interest	135,247	15,317
Cash paid during the year for income taxes	0	0
Supplemental disclosure of noncash investing and financing activities:	'	'
Common stock issued as payment of accounts payable	0	359,754
Accounts payable converted to promissory notes	769,377	0
Supplemental accounts payable	769,377	359,754
Accrued interest converted to promissory notes	26,422	0
Deferred private placement costs charged to contributed capital	0	4,526
Notes payable and accrued interest converted to common shares	1,650,305	120,750
Original issue discount on convertible debt	0	12,600
Beneficial conversion value upon issuance of convertible debt recorded as debt discount and an increase in capital in excess of par value	0	116,600
Common stock issued for fees relating to January 2013 preferred stock private placement	416,666	0
Common stock issued for fees relating to December 2013 warrant exchange program	462,000	0
Common stock issued in payment of preferred stock dividend payable	93,361	0
Refinance of convertible note to note payable	57,500	0
Issuance of warrants as derivative liability instruments and reduction of capital	5,675,634	1,532,347
Increase in warrant liability and reduction in capital as a result of lowering the exercise price on certain warrants	626,328	0
Issuance of warrants as derivative liability instruments	0	92,750
Reclassification of derivative liability to equity due to warrant exercise	14,433,178	0
Reclassification of derivative liability to equity due to warrant exchange program	19,639,465	0
Patent and trademark additions included in accounts payable	$42,490	$0

NATURE_OF_BUSINESS_AND_SUMMARY

NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1. - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation- The accompanying consolidated financial statements include the accounts of 22nd Century Group, its wholly owned subsidiary, 22nd Century Ltd, and 22nd Century Ltd’s wholly owned subsidiaries, Goodrich Tobacco Company, LLC (“Goodrich Tobacco”) and Hercules Pharmaceuticals, LLC (“Hercules Pharma”) (collectively, “the Company”). In May 2012, 22nd Century Ltd acquired from an employee the non-controlling membership units of Goodrich Tobacco that it did not own so that Goodrich Tobacco became a wholly owned subsidiary. All intercompany accounts and transactions have been eliminated.
	Nature of Business- 22nd Century Ltd, is a plant biotechnology company specializing in technology that allows for the level of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The Company owns or exclusively controls 114 issued patents in 78 countries plus an additional 38 pending patent applications.  Goodrich Tobacco and Hercules Pharma are business units for the Company’s (i) premium cigarettes and potential modified risk tobacco products and (ii) smoking cessation product, respectively.
	Reclassifications- Certain items in the 2012 financial statements have been reclassified to conform to the 2013 classification.
	Preferred Stock Authorized- the authorization is for “blank check” preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock. On January 11, 2013 the Company designated the rights of and issued 2,500 shares of Series A-1 Preferred Stock.  As of June 7, 2013, all 2,500 outstanding shares of Series A-1 Preferred Stock were converted into an aggregate 4,166,666 shares of common stock of the Company (see Note 3) and no shares of preferred stock remain outstanding.
	Inventory - Inventories are valued at the lower of cost or market. Cost is determined on the first-in, first-out (FIFO) method.  Inventories are evaluated to determine whether any amounts are not recoverable based on slow moving or obsolete condition and are written off or reserved as appropriate. As of December 31, 2013 and 2012, the Company’s inventory consisted primarily of raw materials, mainly tobacco.
	Fixed assets – Fixed assets are recorded at their acquisition cost and depreciated on a straight line basis over their estimated useful lives ranging from 5 to 10 years.  Depreciation commences when the asset is placed in service.  Cigarette manufacturing equipment purchased in December 2013 in the amount of  $2,762,304 was not placed in service at December 31, 2013 and accordingly, no depreciation was taken.  Certain cigarette manufacturing equipment with a cost of $457,696 will not be used in the Company’s operations and has been recorded as “Machinery and equipment held for resale” on the Company’s Balance Sheet at December 31, 2013.
	Intangible Assets - Intangible assets are recorded at cost and consist primarily of expenditures incurred with third parties related to the processing of patent claims and trademarks with government authorities, as well as costs to acquire patent rights from third parties. The amounts capitalized relate to intellectual property that the Company owns or to which it has exclusive rights. The Company’s intellectual property capitalized costs are amortized using the straight-line method over the remaining statutory life of the primary patent in each of the Company’s two largest patent families, which expires in 2019 and 2028 (the assets’ estimated lives). Periodic maintenance or renewal fees are expensed as incurred.  Annual minimum license fees are charged to expense. Total patent and trademark costs capitalized at December 31, 2013 and 2012 consist of the following:
	During the year ended December 31, 2013, the Company changed the estimated useful life of one of the patent families. The change did not have a material impact on the financial statements.
			December 31,		December 31,
			2013		2012
	Patent and trademark costs	$	2,559,412	$	2,226,586
	Less: accumulated amortization		1,014,543		873,282
	Patent and trademark costs, net	$	1,544,869	$	1,353,304
	The estimated annual amortization expense for the next five years is approximately $177,000.
	Impairment of Long-Lived Assets - The Company reviews the carrying value of its amortizing long-lived assets whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may no longer be recoverable. The Company assesses recoverability of the asset by estimating the future undiscounted net cash flows expected to result from the asset, including eventual disposition. If the estimated future undiscounted net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and its fair value. There was no impairment loss recorded during the year ended December 31, 2013 or 2012.
	Income Taxes - The Company recognizes deferred tax assets and liabilities for any basis differences in its assets and liabilities between tax and GAAP reporting, and for operating loss and credit carry-forwards.
	In light of the Company’s history of cumulative net operating losses and the uncertainty of their future utilization, the Company has established a valuation allowance to fully offset its net deferred tax assets as of December 31, 2013 and 2012.
	The Company’s federal and state tax returns for the years ended September 30, 2011 to December 31, 2012 are currently open to audit under the statutes of limitations.  There are no pending audits as of December 31, 2013.
	Refundable taxes and tax credits – The Company accounts for income tax refunds or tax refundable tax credits as discrete items and recognized the amount in the period in which the funds are received. During the year ended December 31, 2013, the Company received notice from the New York State Department of Taxation and Finance of a no change audit with respect to its income tax return filed for the period ending September 30, 2011. The subject return contained a refundable credit in the amount of $122,000.  The refund was recorded as other income in the Company’s consolidated statement of operations. There were no such transactions during the year ended December 31, 2012.
	Stock Based Compensation - The Company uses a fair-value based method to determine compensation for all arrangements under which Company employees and others receive shares, options or warrants to purchase common shares of 22nd Century Group. Stock based compensation expense is recorded over the requisite service period based on estimates of probability and time of achieving milestones and vesting. For accounting purposes, the shares will be considered issued and outstanding upon vesting.
	Debt Discounts - Original issue discount (“OID”) is recorded equal to the difference between the cash proceeds, after allocation to warrants issued or issuable upon payment of the debt, and the face value of the debt when issued and amortized as interest expense during the term of the debt.
	When the convertible feature of the conventional convertible debt is issued, the embedded conversion feature is evaluated to determine if bifurcation and derivative treatment is required and whether there is a beneficial conversion feature.  When the convertible debt provides for an effective rate of conversion that is below market value, this feature is characterized as a beneficial conversion feature (“BCF"). Prior to the determination of the BCF, the proceeds from the debt instrument were first allocated between the convertible debt and any embedded or detachable free standing instruments that are included, such as common stock warrants. The proceeds allocated to any warrants are recorded as a debt discount.
	The debt discount is amortized to interest expense over the life of the debt. In the case of any conversion prior to the maturity date there will be an unamortized amount of debt discount that relates to such conversion.  The pro rata amount of unamortized discount at the time of such conversion is charged to interest expense as accelerated amortization of the discount.  The fair value of warrants issued at the time of conversion is recorded as a reduction of the amount applied to the common stock issued in the conversion and to the extent that the fair value of warrants exceeds the carrying value of the debt a charge to interest expense results for such excess amount.
	Revenue Recognition - The Company recognizes revenue from product sales at the point the product is shipped to a customer and title has transferred.  Revenue from the sale of the Company’s products is recognized net of cash discounts, sales returns and allowances. Cigarette federal excise taxes are included in net sales and accounts receivable billed to customers, except on sales of SPECTRUM research cigarettes and exported cigarettes in which such taxes do not apply.
	The Company was chosen to be a subcontractor for a 5-year government contract between RTI International (“RTI”) and the National Institute on Drug Abuse (“NIDA”) to supply NIDA research cigarettes. These government research cigarettes are distributed under the Company’s mark, SPECTRUM. The Company delivered approximately 12 million SPECTRUM research cigarettes during the year ended December 31, 2012 and 2011 and recognized the related revenue of approximately $807,000. There were no SPECTRUM cigarettes delivered during the year ended December 31, 2013.  Future revenue under this arrangement is expected to be related to the delivery of SPECTRUM and will be recognized at the point the product is shipped and title has transferred.  In September 2013, the Company received a purchase order for an additional 5.5 million SPECTRUM research cigarettes that will be manufactured and shipped in January 2014.  Total revenue from this order will be approximately $448,000 and a down payment on the order was received in the fourth quarter of 2013 in the amount of $179,014.  The down payment has been recorded as deferred revenue on the Company’s balance sheet at December 31, 2013.
	The Company licenses its patented technology to third parties.  Revenue is recognized from licensing arrangements as contractually defined in licensing agreements. The Company accounts for milestones elements contained in licensing agreements in accordance with ASC 605. On October 1, 2013, 22nd Century Ltd entered into a worldwide Research License and Commercial Option Agreement (the “Agreement”) with British American Tobacco (Investments) Limited (“BAT”), a subsidiary of British American Tobacco plc, that grants BAT access to 22nd Century Ltd’s patented technology which alters levels of nicotinic alkaloids in tobacco plants.  Simultaneous with the signing of the Agreement, BAT paid the Company a non-refundable $7,000,000.  The Company will be entitled to receive additional payments from BAT of up to an additional $7,000,000 during the term of the Research License in the event certain milestones are met by BAT with respect to its research and development of the patent rights and licensed intellectual property rights licensed by the Company to BAT. No amount related to the additional research milestones were recognized during 2013. During the term of the Research License, BAT will have the option to enter into a Commercial License agreement which will provide for future royalty payments based on sales.  A portion of the patented technology sublicensed to BAT is exclusively licensed to 22nd Century Ltd by a third party licensor. Pursuant to the terms of the license agreement with such licensor, 22nd Century Ltd is obligated to make a royalty payment to the licensor. 22nd Century Ltd estimates the payment to be approximately  $414,000, subject to the mutual agreement of 22nd Century Ltd and the third party licensor.
	Derivatives - We do not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and then is revalued at each reporting date, with changes in fair value reported in the consolidated statement of operations.  The methodology for valuing our outstanding warrants classified as derivative instruments utilizes a lattice model approach which includes probability weighted estimates of future events including volatility of our common stock. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.
	Research and Development -Research and development costs are expensed as incurred.
	Loss Per Common Share - Basic loss per common share is computed using the weighted-average number of common shares outstanding.  Diluted loss per share is computed assuming conversion of all potentially dilutive securities. Potential common shares outstanding are excluded from the computation if their effect is anti-dilutive.
	Commitment and Contingency Accounting - The Company evaluates each commitment and/or contingency in accordance with the accounting standards, which state that if the item is more likely than not to become a direct liability, then the Company will record the liability in the financial statements. If not, the Company will disclose any material commitments or contingencies that may arise.
	Use of Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.
	Fair Value of Financial Instruments -  Financial instruments include cash, receivables, accounts payable, accrued expenses, notes payable, demand bank loan, convertible notes payable and warrant liability.  Other than warrant liability and convertible notes payable, fair value is assumed to approximate carrying values for these financial instruments, since they are short term in nature, they are receivable or payable on demand, or had stated interest rates that approximate the interest rates available to the Company as of the reporting date.  The determination of the fair value of the warrant liability includes unobservable inputs and is therefore categorized as a Level 3 measurement, as further discussed in Note 10.  There are no convertible notes outstanding at December 31, 2013.

FINANCIAL_CONDITION

FINANCIAL CONDITION	12 Months Ended
	Dec. 31, 2013
Financial Condition Disclosure [Abstract]	'
Financial Condition Disclosure [Text Block]	'
	NOTE 2. – FINANCIAL CONDITION
	At December 31, 2013, the Company had current assets of $7,744,115 and current liabilities of $984,334 resulting in positive working capital of $6,759,781.  Cash on hand at December 31, 2013 was $5,830,599.  During the year ended December 31, 2013, the Company has improved its balance sheet and cash position primarily through a series of equity transactions that realized net proceeds of approximately $7,529,000 and completion of a worldwide Research License and Commercial Option Agreement generating gross royalties of $7,000,000. As a result of the above referenced transactions, the Company believes it will have adequate cash reserves to sustain operations and meet all current obligations as they come due for a period in excess of 12 months.

JANUARY_2013_PREFERRED_STOCK_P

JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT	12 Months Ended
	Dec. 31, 2013
January 2013 Preferred Stock Private Placement [Abstract]	'
January 2013 Preferred Stock Private Placement	'
	NOTE 3. - JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT
	On January 11, 2013, the Company sold  2,500 shares of newly created Series A-1  10% Convertible Preferred Stock (the “Series A-1 Preferred Stock”) and warrants for $2.5 million. Net proceeds from this issuance were $2.035 million.
	The shares of Series A-1 Preferred Stock were initially convertible into a total of  4,166,666 shares of the Company’s common stock at a conversion price of $0.60 per share (the “Conversion Price”), subject to future adjustments, which have subsequently expired with no change to the conversion price. The Series A-1 Preferred Stock paid a  10.0% annual cash dividend, which was payable in shares of our common stock in certain circumstances, and had a liquidation preference equal to the stated value of the Series A-1 Preferred Stock of $1,000 per share plus any accrued and unpaid dividends thereon. The Series A-1 Preferred Stock had no voting rights.
	The preferred stockholders did not have mandatory redemption rights, nor did the Company have an unconditional obligation to issue a variable number of shares.  Further, there was a limit on the number of shares that were issuable upon conversion.  Accordingly, the Series A-1 Preferred Stock was classified as permanent equity.  Based on the fact that the host instrument is more akin to equity, it was further determined that bifurcation of the embedded conversion feature was not required.
	The Company also issued to the Purchasers of the Series A-1 Preferred Stock a Series A warrant (the “Series A Warrant”), a Series B warrant (the “Series B Warrant”), and a Series C warrant (the “Series C Warrant”) (with the Series A Warrant, Series B Warrant and Series C Warrant being collectively referred to herein as the “Warrants”). The Series A Warrant allows the Purchasers the right to acquire, initially before any adjustments to the conversion price, up to an additional  4,166,666 shares of the Company’s common stock at an exercise price of approximately $0.72 per share over a period of five (5) years. The Series A Warrant also allows for such warrant to be exercised on a cashless basis. The Series B Warrant allowed the Purchasers a one-year period to exercise an overallotment option as contained in the Series B Warrant to purchase, initially before any adjustments to the conversion price, up to an additional aggregate of  2,083,334 shares of the Company’s common stock at a price of $0.60 per share. Since the Purchasers fully exercised the Series B Warrant, the Purchasers have the right to exercise the Series C Warrant to acquire, initially before any adjustments to the conversion price, an additional aggregate of  2,083,334 shares of the Company’s common stock at an exercise price of approximately $0.72 per share over a period of five (5) years. The Series C Warrant allows for such warrant to be exercised on a cashless basis.
	The warrants have a “down round provision” which results in the warrants being classified and reported as derivative liabilities for accounting purposes and marked to market at each balance sheet date.  At the date of the issuance of these warrants, including lock-up warrants, the fair value was estimated to be $6,022,319, which exceeded the net consideration received in the offering of $2,034,664, resulting in an immediate charge to “other expense – warrant liability loss – net” in the amount $3,987,655.  During June 2013,  982,300 Series B Warrant shares were exercised resulting in net proceeds to the Company in the amount of $542,229.  In addition, the exercise of the Series B Warrant shares resulted in a reduction in the warrant liability and an increase in capital in the amount of $204,513.  The exercise of the  982,300 Series B Warrant shares triggered the issuance of a like amount of Series C Warrant shares.  The Series C Warrant shares include a “down round provision” and results in a derivative liability upon issuance.  At the date of issuance of the  982,300 Series C Warrant shares the fair value was estimated to be $711,675.  During July 2013,  1,101,034 Series B Warrant shares were exercised resulting in net proceeds to the Company in the amount of $607,771.  In addition, the exercise of the Series B Warrant shares resulted in a reduction in the warrant liability and an increase in capital in the amount of $671,219.  The exercise of the 1,101,034 Series B Warrant shares triggered the issuance of a like amount of Series C Warrant shares.  The Series C Warrant shares include a “down round provision” and resulted in a derivative liability upon issuance.  At the date of the issuance of these warrants the fair value was estimated to be $1,622,069, which exceeded the sum of the net consideration received in the offering of $607,771 and the reclassification of warrant liability to capital of $671,219, resulting in an immediate charge to “other expense – warrant liability loss – net” in the amount of $343,079.
	As of June 30, 2013, the Company accrued a dividend payable to the preferred shareholders in the amount of $93,361. On May 9, 2013 the Company executed an agreement with the Purchasers of the Series A-1 Preferred Shares to pay certain accrued dividends on the Series A-1 Preferred Stock in shares of the Company’s common stock in lieu of cash.  In accordance with the agreement, on July 12, 2013, the Company issued  161,153 shares of common stock to the Purchasers of the Series A-1 Preferred Shares in payment of the accrued dividends payable at June 30, 2013, resulting in an increase in capital in the amount of $93,361. No dividends are accrued or payable subsequent to the payment of this dividend.
	On August 1, 2013, the Company entered into an agreement with the holders of its Series A Warrants and Series C Warrants for such holders to exercise a portion of such Series C Warrants to acquire an aggregate of  1,666,666 shares of the Company’s common stock for a cash payment to the Company of $1,000,000 (“Warrant Exercise Agreement”).  Prior to the Company and such holders of the Series A Warrants and the Series C Warrants entering into such Warrant Exercise Agreement, the Series A Warrants and the Series C Warrants could have been exercised by such holders on an entirely cashless basis.  In exchange for the cash exercise of such portion of the Series C Warrants, the Company reduced the exercise price of all of the Series A Warrants and Series C Warrants from $0.72 to $0.60 per share.  The reduced exercised price resulted in an increase in the warrant liability associated with the Series A Warrants and Series C Warrants and a corresponding reduction in capital in the amount of $626,328.  In addition, if on a specified date in the future when the shares of common stock of the Company acquired upon this cash exercise of the Series C Warrants become freely tradable pursuant to Rule 144 of the Securities Act of 1933, as amended, the Company’s common stock (as measured by the five trading days before such date) is less than $1.31 per share (the “Measurement Price”), then the Company must reimburse the holders of these warrants up to an amount equal to the difference between $1.31 and the Measurement Price (subject to a floor of $0.60 per share) multiplied by the number of shares of common stock acquired upon the cash exercise of such Series C Warrants pursuant to the terms of the Warrant Exercise Agreement (the “Limited Market Make-Good Provision”).  Notwithstanding the foregoing, the Company has no obligation to pay such amounts under the Limited Market Make-Good Provision until and unless the holders of the shares actually incur a loss on the sales of such shares of common stock for a price below the Measurement Price.  The Limited Market Make-Good Provision created a contingent liability that must be evaluated and recorded based on its fair value at each reporting date.  The maximum exposure related to this obligation is $1,183,333.  Upon entering into this agreement, management estimated the fair value of the instrument and recorded a current liability and corresponding reduction in capital of approximately $290,000 as of September 30, 2013.  At December 31, 2013, management estimated the fair value of the instrument to be zero primarily as a result of the increase in the underlying value of the Company’s common stock and the short period of time remaining to the date of the Measurement Price.  Accordingly, the Company reversed the $290,000 current liability at December 31, 2013 that was established at September 30, 2013.  The Series C Warrant holders exercised the cash option on August 5, 2013.  The cash exercise of these Series C Warrant shares resulted in a reduction in the warrant liability and an increase in capital in the amount of $3,172,000.   As a result of this Warrant Exercise Agreement, an additional $60,000 commission was paid to Chardan Capital Markets, LLC.
	On August 6, 2013, the Series A and Series C Warrant holders exercised on a cashless basis at $0.60 per share  147,916 and  416,668 Series A and Series C Warrant shares, respectively, resulting in the issuance of  360,000 shares of common stock of the Company.  The cashless exercise of these Series A and Series C Warrant shares resulted in a reduction in the warrant liability and an increase in capital in the amount of $1,074,670.  On September 20, 2013, the Series A Warrant holders exercised on a cashless basis at $0.60 per share  339,861 Series A Warrants resulting in the issuance of  177,300 shares of common stock of the Company.  This cashless exercise of these Series A Warrant shares resulted in a reduction in the warrant liability and an increase in capital in the amount of $608,419. Between October 3, 2013 and December 26, 2013, the Series A Warrant holder exercised on a cashless basis at $0.60 per share 3,678,889 Series A warrants resulting in the issuance of 1,972,976 shares of common stock of the Company.  This cashless exercise of these Series A Warrant shares resulted in a reduction in the warrant liability and an increase in capital in the amount of $7,712,170.
	In connection with the issuance of the Series A-1 Preferred Stock, the Company paid Chardan Capital Markets, LLC a commission equal to (i) ten percent (10%) of the cash received by the Company and (ii)  416,666 shares of common stock. In the event the Purchasers exercise for cash any of the Warrants, then the Company will also pay an additional cash commission to Chardan Capital Markets LLC equal to eight percent (8%) (with no additional equity) of any such additional cash amounts received by us. For the year ended December 31, 2013, the Company paid an aggregate total of $160,000 in commissions to Chardan Capital Markets, LLC in conjunction with the cash exercise of Series B and Series C Warrant shares, which has been reflected as a reduction of the equity proceeds.
	In conjunction with the Series A-1 Preferred Stock private placement, the Company issued  203,167 lock-up warrants to stockholders that participated in previous private placements. These warrants were valued at $168,402 and are considered liabilities due to a down round provision. This amount was also considered a cost of the Series A-1 Preferred Stock private placement. After deducting fees and expenses, the aggregate net proceeds from the sale of the Series A-1 Preferred Shares and the Warrants were $2.035 million. The net proceeds were earmarked for the payment of certain financial obligations and for working capital and other general corporate purposes.

MAY_and_NOVEMBER_2012_PRIVATE_

MAY and NOVEMBER 2012 PRIVATE PLACEMENT	12 Months Ended
	Dec. 31, 2013
May and November 2012 Private Placement [Abstract]	'
MAY and NOVEMBER 2012 PRIVATE PLACEMENT	'
	NOTE 4. - MAY and NOVEMBER 2012 PRIVATE PLACEMENT
	On May 15, 2012 the Company issued 1,710,833 shares of its common stock and warrants to purchase up to 1,710,833 shares of its common stock for total consideration of $1,026,500 consisting of: $786,500 in cash, cancellation by a vendor of $150,000 in accounts payable and the exchange by an employee of his 4% minority interest in Goodrich Tobacco for stock and warrants valued at $90,000 in the offering.  The warrants issued have an original exercise price of $1.00 per share, a five year term and a “down round provision,” which results in the warrants being classified and reported as derivative liabilities for accounting purposes, and marked to market at each balance sheet date.  At the date of issuance of these warrants the value was estimated to be $1,841,000 which exceeded the total consideration received in the offering by $814,500 resulting in an immediate charge to other income and expense - warrant liability - net for this amount.  This private placement constituted a “down round” for purposes of all previously issued warrants and the December 14, 2011 Convertible Notes and resulted in adjustments to the exercise price, conversion price and the number of shares issuable upon exercise or conversion of these previously issued securities. Three executive officers of the Company acquired 44,000 shares and warrants for $26,400 in cash.
	On November 9, 2012 the Company issued 3,238,000 shares of its common stock and warrants to purchase up to 1,619,000 shares of its common stock for total consideration of $809,500 consisting of: $681,000 in cash, cancellation by vendors of $98,500 in accounts payable and cancellation of $30,000 in directors fees owed to two directors.  The warrants issued have an original exercise price of $1.00 per share, a five year term and a “down round provision,” which results in the warrants being classified and reported as derivative liabilities for accounting purposes, and marked to market at each balance sheet date. At the date of issuance of these warrants the value was estimated to be $353,747 which reduced the amount recorded to additional paid in capital.  This private placement constituted a “down round” for purposes of all previously issued warrants and the December 14, 2011 Convertible Notes and resulted in adjustments to the exercise price, conversion price and the number of shares issuable upon exercise or conversion of these previously issued securities. Two executive officers of the Company acquired a total of 1,080,000 shares and 540,000 warrants for $270,000 in cash. Two directors of the Company acquired a total of 120,000 shares and 60,000 warrants in lieu of payment of $30,000 of director fees.

MACHINERY_AND_EQUIPMENT

MACHINERY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
MACHINERY AND EQUIPMENT	'
	NOTE 5. – MACHINERY AND EQUIPMENT
	Machinery and equipment at December 31, 2013 and 2012 consists of the following:
		December 31,		December 31,
		2013		2012
	Cigarette manufacturing equipment	$	3,220,000	$	-
	Office furniture, fixtures and equipment		17,059		9,106
	Leasehold improvements		14,500		-
	Deposit for purchase of machine parts and other assets		210,000		-
			3,461,559		9,106
	Less: cigarette manufacturing equipment held for resale		457,696		-
			3,003,863		9,106
	Less: accumulated depreciation		6,103		3,076
	Machinery and equipment, net	$	2,997,760	$	6,030
	On December 11, 2013, the Company closed on a $3,220,000 purchase of certain cigarette manufacturing equipment from a company located in North Carolina that was liquidating under Chapter 7 of the U.S. Bankruptcy Code.  A certain portion of the equipment will not be required for the Company’s cigarette manufacturing operations and will be subsequently listed for sale in the first quarter of 2014 in order to offset the purchase price of the equipment.  The Company allocated $457,696 of the purchase price to these assets and classified them as machinery and equipment held for resale in the current asset section of the balance sheet at December 31, 2013.  The remaining cigarette manufacturing equipment, with a cost of $2,762,304, was not placed in service as of December 31, 2013, and accordingly, no depreciation was recorded.
	In December 2013, the Company made a $210,000 deposit to the bankruptcy trustee of a company located in North Carolina that is liquidating under Chapter 11 of the U.S. Bankruptcy Code to purchase various cigarette manufacturing equipment parts, office furniture and fixtures, vehicles and computer software and equipment. On January 13, 2014, the transaction closed and the Company successfully purchased the subject assets for the amount of the $210,000 deposit.

DEMAND_BANK_LOAN

DEMAND BANK LOAN	12 Months Ended
	Dec. 31, 2013
Demand Bank Loan [Abstract]	'
DEMAND BANK LOAN	'
	NOTE 6. - DEMAND BANK LOAN
	The demand loan that is among the Company’s short term liabilities is payable to a commercial bank under a revolving credit agreement and is guaranteed by an executive officer of the Company.   This loan had a balance of $174,925 at December 31, 2013 and 2012. The Company is required to pay interest monthly at an annual rate of 0.75% above the prime rate, or 4.00% at December 31, 2013 and 2012. The Company is current in meeting this interest payment obligation. The terms of the demand loan includes an annual “clean-up” provision, which requires the Company to repay all principal amounts outstanding for a period of 30 consecutive days every year. The Company has not complied with this requirement; however, the bank has not demanded payment. The bank has a lien on all the Company’s assets.

NOTES_PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
NOTES PAYABLE	'
	NOTE 7. - NOTES PAYABLE
	Notes payable consisted of the following as of the dates set forth below:
			December 31,		December 31,
			2013		2012
	Note dated March 31, 2011	$	-	$	77,000
	Note dated January 25, 2011		-		140,000
	Note dated March 13, 2013 and March 30, 2011		-		350,000
	Note dated March 22, 2012 and April 13, 2012		-		50,000
	Note dated January 15, 2013		-		-
	Note dated January 23, 2013		-		-
	Note dated January 24, 2013		-		-
	Note dated February 1, 2013		-		-
	Notes payable	$	-	$	617,000
	Convertible Note Dated March 31, 2011 (unsecured) -   On March 31, 2011, the Company issued a note to a vendor in the original amount of $237,000 as satisfaction of past due invoices previously recorded by the Company in accounts payable. The note bears interest at an annual rate of  9%.  In December 2011 the note was amended and the principal was reduced by a cash payment of $50,000 and $100,000 of the notes was exchanged for $115,000 of a portion of the Convertible Notes issued December 14, 2011.  The Company made a $10,000 principal payment in May 2012, leaving a remaining balance of $77,000 as of December 31, 2012.  On January 18, 2013 the note was paid in full together with accrued interest.
	Note Dated January 25, 2011 (unsecured)  - On January 25, 2011, the Company issued a note for $140,000 to a shareholder as satisfaction of the balance due for principal and interest on a matured note that was not paid in cash or converted to common stock of 22nd Century Group and warrants to purchase shares of common stock of 22nd Century Group. The note bears interest at  12% and was due on October 1, 2013 together with accrued interest.  In July 2013, the Company made a $30,000 payment that was applied to the accrued interest on the note.  On October 2, 2013, the Company made a payment to the note holder in the amount of $155,153 in full satisfaction of the note and all accrued interest.
	Note Dated March 13, 2013 and March 30, 2011 (unsecured)  - On March 30, 2011, the Company issued a note to a vendor in the amount of $350,000 as satisfaction of past due invoices previously recorded by the Company in accounts payable. The note bears interest at an annual rate of  4%. Principal and accrued interest were due on July 1, 2012.  As of December 31, 2012, the outstanding principal of $350,000 on this note remained unpaid.  In January 2013, the Company repaid $268,286 of the note principal. The remaining unpaid balance of $81,714 plus accrued interest of $25,582 and outstanding accounts payable of $67,704 were refinanced into a new unsecured note with a principal balance of $175,000 dated March 13, 2013, which bears interest at 5% and matures on July 1, 2014 or sooner if the Company receives license revenue or financing of at least $1,500,000 prior to maturity.  On October 11, 2013, the Company made a payment to the note holder in the amount of $181,233 in full satisfaction of the note and all accrued interest.
	Note Dated March 22, 2012 and April 13, 2012 (secured)  - On March 22, 2012 and April 13, 2012, the Company issued two notes in the amount of $25,000 each, originally due on October 1, 2012. The notes were secured by all assets of the Company and its subsidiaries. An officer of the Company is the managing member of the lender. The notes bear interest at an annual rate of  15%. The outstanding principal on this note as of December 31, 2012 was $50,000.  Principal and accrued interest of both notes were paid in full by the Company on January 22, 2013.
	Note Dated January 15, 2013 (unsecured)  - On January 15, 2013, the Company issued a note to a vendor in the amount of $226,780 as satisfaction of past due invoices previously recorded by the Company in accounts payable and accrued interest. The note bears interest at an annual rate of  8%.  The outstanding principal and accrued interest was due on October 18, 2013 or sooner if the Company closes an in-licensing agreement in which the Company or a subsidiary receives an up-front payment of at least $1 million.  On August 2, 2013, the Company made a $100,000 payment to the note holder that was applied against the note and accrued interest leaving the note principal balance at $136,671.  On October 2, 2013, the Company made a payment to the note holder in the amount of $138,469 in full satisfaction of the note and all accrued interest.
	Note Dated January 23, 2013 (unsecured)  - On January 23, 2013, the Company issued a $150,000 note to an executive officer of the Company.  The note bears interest at an annual rate of  15%.  The outstanding principal and accrued interest was due on October 1, 2013. On October 2, 2013, the Company made a payment to the note holder in the amount of $165,473 in full satisfaction of the note and all accrued interest.
	Note Dated January 24, 2013 (unsecured)  - On January 24, 2013, the Company issued a note to a former Convertible Note holder in the amount of $58,340 to discharge $57,500 in Convertible Notes held by the lender plus accrued interest.  The note bears interest at an annual rate of  15%.  The outstanding principal and accrued interest was due on July 24, 2013.  On July 16, 2013, the note was paid in full together with all accrued interest.
	Note Dated February 1, 2013 (unsecured)  - On February 1, 2013, the Company issued a note to a vendor in the amount of $474,893 as satisfaction of past due invoices previously recorded by the Company in accounts payable. The note bears interest at an annual rate of 5%.  The outstanding principal and accrued interest is due on October 1, 2013 or sooner if the Company closes an in-licensing agreement in which the Company or any affiliate receives an up-front payment of at least $1.5 million.  On October 2, 2013, the Company made a payment to the note holder in the amount of $490,701 in full satisfaction of the note and all accrued interest.

CONVERTIBLE_NOTES

CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2013
Convertible Notes [Abstract]	'
CONVERTIBLE NOTES	'
	NOTE 8. - CONVERTIBLE NOTES
	ISSUED DECEMBER 14, 2011
	The Company issued convertible notes on December 14, 2011 in a negotiated sale with  24 investors in the total face amount of $1,926,250 (“Convertible Notes”). The Convertible Notes were sold for $1,675,000 - an original issue discount of $251,250. The Convertible Notes did not bear interest and the total face amount was due December 14, 2012. The Convertible Notes could be converted, at the option of each holder, in whole or in part, into shares of the Company’s common stock at $0.75 per share at which time the holder shall also receive warrants equal to  120% of the number of shares of Company common stock into which such Convertible Notes have been then converted. The Company could also force the investors to decide whether to convert by sending a 15-day written notice in which each investor is forced to decide whether to convert or receive payment in full. Such warrants have a term of five years and an exercise price of $1.50 per share of common stock.  The Convertible Notes contained “down round” provisions which provided for adjustments to the conversion price if the Company issues shares of common stock of 22nd Century Group at a price that is less than the exercise price. The conversion feature was not considered to be a derivative because it does not have a net cash settlement provision as a result of the limited market and trading activity for the underlying stock at this time.
	The Company’s common stock closed at $0.90 per share on December 14, 2011, which is greater than the portion of the conversion price under the Convertible Notes allocated to the underlying common shares. This difference is a beneficial conversion feature (BCF) which was valued at $1,062,758 at the issue date and recorded as debt discount and additional paid in capital. This BCF was amortized over the one year life of the Convertible Notes.
	Three of the Company’s executive officers at the time of issuance acquired a portion of the Convertible Notes - with a face value of $368,000, for cash of $105,000 and conversion of $215,000 short term unsecured  12% notes issued by the Company earlier in 2011.
	As of December 31, 2012, the OID and BCF discounts were fully amortized, and therefore no amortization was recorded during the year ended December 31, 2013. During the year ended December 31, 2012, $1,284,363 of the debt discount was amortized and recorded as interest expense related to the OID and BCF discounts.
	During the year ended December 31, 2012, a portion of the Convertible Notes with a face amount of $120,750 (carrying value at time of conversion of approximately $55,000, net of unamortized discount) were converted into  161,494 shares of common stock and warrants to purchase  193,793 shares of common stock. As a result of the conversion, the unamortized portion of the debt discount amounting to approximately $66,000 was immediately charged to interest and a derivative warrant liability valued at approximately $152,000 was recorded.  The difference in the warrant value and debt relieved amounting to approximately $31,000 was also charged to interest expense.  Included in conversions of the Convertible Notes during the year ended December 31, 2012 was a note converted by an officer with a face amount of $86,250 converted into  115,000 shares of common stock and warrants to purchase  138,000 shares of common stock.
	At December 31, 2012, Convertible Notes with a total face and carrying value of $1,805,500 remained outstanding; of this amount $1,523,750 were extended by agreement with the note holders to April 14, 2013 at  15% interest per annum.  Two convertible note holders did not execute agreements to extend their notes. In connection with the issuance of the Series A-1 Preferred Stock in January 2013, the Convertible Note holders entered into lock-up agreements with the Company and received additional warrants (five year term at $1.50 exercise price) to purchase  219,909 shares of common stock, and have the same rights as the warrants in the original December 2011 Convertible Note agreement. The lock-up agreement restricted the Convertible Note holders’ ability to sell any of the shares received as a result of the conversion of the Convertible Notes.
	Of the $1,805,500 in convertible notes outstanding at December 31, 2012, $1,408,750 of the Convertible Notes (together with accrued interest) were converted into  2,035,720 shares of common stock and five-year warrants (which includes lock-up warrants) to purchase  2,662,769 shares of common stock at $1.50 per share during the period from January 1, 2013 to February 6, 2013. The Company discharged the remaining convertible notes of $396,750 by payments in cash of $339,250 and the Company refinanced $57,500 into a new note that was paid in full in July 2013.  Of the Convertible Notes paid in cash, $247,250 was held by an executive officer. The executive officer subsequently issued the Company a new promissory note in the amount of $150,000 that matured on October 1, 2013 (see Note 7). None of the Convertible Notes issued on December 14, 2011 remain outstanding as of December 31, 2013.
	ISSUED AUGUST 9, 2012
	The Company issued convertible notes on August 9, 2012 in a negotiated sale with 4 investors in the total face amount of $222,600. The convertible notes were sold for $210,000 - an original issue discount (OID) of $12,600. The convertible notes did not bear interest and the total face amount was due August 9, 2013 together with warrants equal to 50% of the number of shares of Company common stock into which such convertible notes are converted.  These warrants were valued at $92,750 and represent additional debt discount and warrant liability. The convertible notes can be converted, at the option of each holder, in whole or in part, into shares of the Company’s common stock at $0.60 per share at which time the holder shall also receive warrants equal to  100% of the number of shares of Company common stock into which such convertible notes are converted. Additional warrants issued as a result of conversion will be valued and recorded as a warrant liability at that time and will reduce the equity recorded as a result of the conversion.  In the event the warrant value exceeds the amount of equity, an immediate charge to other expense will be recorded. The warrants issued upon conversion or maturity will have a term of five years and an exercise price of $1.00 per share of common stock.  The conversion feature was not considered to be a derivative because it does not have a net cash settlement provision as a result of the limited market and because of the trading activity for the underlying stock at the time. The warrants to be issued upon conversion or maturity have a “down round provision” and will be classified as derivatives for accounting purposes, and are reported as a liability and marked to market at each balance sheet date.
	The Company’s common stock closed at $0.45 per share on August 9, 2012, which is greater than the portion of the conversion price under the convertible notes allocated to the underlying common shares. This difference is a beneficial conversion feature (BCF) which was valued at $116,600 at the issue date and recorded as debt discount and additional paid in capital. This BCF is being amortized over the one year life of the convertible notes.
	During the years ended December 31, 2013 and 2012, $134,296 and $87,654 of debt discount was amortized and recorded as interest expense related to the OID, warrant and BCF discounts, leaving no unamortized debt discount as of December 31, 2013.
	During August 2013, all of the convertible notes issued on August 9, 2012 with a carrying value of $222,600 were converted into 371,000 shares of common stock and five-year warrants to purchase 371,000 shares of common stock at $1.00 per share.
	The warrants issued in conjunction with the note conversions during August 2013 were recorded at fair value at the time of issuance amounting to $731,662. Since the warrants are considered a derivate liability, the excess of the fair value of the warrants at the time of issuance above the face amount of the notes converted was immediately recorded as additional interest expense in the amount of $509,062.
	The following table summarizes convertible notes and related discount.
		December 31,		December 31,
		2013		2012
	Face value of all convertible notes payable through maturity	$	-	$	2,028,100
	Less unamortized original issue discount		-		-63,787
	Less unamortized discount related to BCF		-		-70,509
	Convertible Notes, net of unamortized debt discount	$	-	$	1,893,804
	Carrying value of December 14, 2011 Convertible Notes	$	-	$	1,805,500
	Carrying value of August 9, 2012 Convertible Notes	$	-	$	88,304

DUE_FROM_RELATED_PARTY

DUE FROM RELATED PARTY	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
DUE FROM OR TO RELATED PARTY	'
	NOTE 9. - DUE FROM RELATED PARTY
	The Company has conducted transactions with a related party, Alternative Cigarettes, Inc. (“AC”).  AC is entirely owned by certain shareholders of the Company, including the CEO.  AC shares office space and employee services with the Company. During the year ended December 31, 2011 the Company acquired its  MAGIC trademark from AC for a purchase price of $22,500. During the years ended December 31, 2013 and 2012, transactions with AC consisted mainly of repayments and advances. The net amount due from AC amounted to $42,069 as of December 31, 2013 ($36,969 as of December 31, 2012). No interest has been accrued or paid on amount due from or to AC and there are no repayment terms.

WARRANT_EXCHANGE_PROGRAM_AND_W

WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK	12 Months Ended
	Dec. 31, 2013
Warrants For Common Stock [Abstract]	'
WARRANTS FOR COMMON STOCK	'
	NOTE 10. - WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK
	WARRANT EXCHANGE PROGRAM
	The Company had 19,616,308 warrants for common stock outstanding at September 30, 2013.  These warrants contain “down round” provisions and anti-dilution features that provide for adjustments to the exercise price and number of warrants outstanding if the Company issues common shares of stock of 22nd Century Group at a price that is less than the respective warrant exercise prices.  These provisions require that these warrants be classified as derivatives for accounting purposes, which means they are reported as a liability and adjusted to fair value at each balance sheet date.  On November 14, 2013, the Company initiated a warrant exchange program (the “Warrant Exchange Program”) with the goal of reducing the Company’s warrant liability.  To that end, the Company offered financial inducements to certain warrant holders to (1) exercise their warrant on a cash basis, (2) exercise their warrant on a cashless basis, or (3) agree to have the “down round provision” or anti-dilution feature removed from their warrant in exchange for additional warrant coverage.  The warrants holders also had the option to maintain the terms and conditions of their original warrant.  Management and the Company’s Board of Directors were prohibited from participating in the Warrant Exchange Program. As a result of the cash and cashless exercise of warrants, there is a reduced number of outstanding warrants, and as a result of the removal of the “down round” provisions and anti-dilution features on other warrants, they are no longer required to be classified as a derivative liability. The Warrant Exchange Program that ended on December 12, 2013, generated gross proceeds of $3,559,763 and resulted in the issuance of 5,348,172 shares of the Company’s common stock from the cash exercise of warrants.  The issuance of 156,197 shares of the Company’s common stock resulted from the exercise of 513,949 warrants that were exercised on a cashless basis.  As an inducement for warrant holders to agree to remove their “down round” provision and anti-dilutions feature from their warrant, 138,666 additional warrants were issued.  As a result of the Warrant Exchange Program, there are 6,732,088 warrants outstanding at December 31, 2013 that do not contain the “down round” provisions or anti-dilution features.  The Company calculated the cost of inducement as the difference between the fair value of the warrants immediately after the Warrant Exchange Program was closed on December 12, 2013, less the fair value of the warrants immediately prior to Warrant Exchange Program completion. The Company estimated the total cost of inducement to be $3,736,313, and this expense has been recorded as an “Other Expense” on the consolidated statements of operations and as an increase to the derivative warrant liability, and subsequently reversed into capital.  The Company paid $320,378 and issued 300,000 shares of the Company’s common stock to Chardan Capital Markets, LLC (“Chardan”) in conjunction with the Warrant Exchange Program.  The fair value of the 300,000 shares issued to Chardan in the amount of $462,000 is included as a component of the total cost of inducement.
	WARRANTS FOR COMMON SOCK
	In connection with the January 25, 2011 Private Placement and reverse merger into a public company, the Company issued five year warrants (“January 25, 2011 Warrants”) to purchase shares of common stock of 22nd Century Group. These warrants contain “down round” provisions and anti-dilution features which provide for adjustments to the exercise price if the Company issues common shares of stock of 22nd Century Group at a price that is less than the respective warrant exercise prices. This provision and features require these warrants be classified as derivatives for accounting purposes, which means they are reported as a liability and marked to market at each balance sheet date. As a result of the equity securities issued during 2012, the “down round” provision and anti-dilution feature of the January 25, 2011 Warrants were triggered and the adjusted warrants outstanding as of December 31, 2012 were  5,482,055 with an exercise price of $2.73 per share and  3,947,232 with an exercise price of $1.39 per share. As a result of equity securities issued during the year ended December 31, 2013, the cashless conversion of  1,160,080 warrants during the third quarter of 2013, and the effects of the Warrant Exchange Program, the January 25, 2011 Warrants now amount to  3,455,039 warrants with an exercise price of $2.21 per share, 3,062,665 warrants with an exercise price of $1.96 per share, 110,336 warrants with an exercise price of $1.20 per share and  374,007 warrants with an exercise price of $1.27 per share outstanding as of December 31, 2013.  As a result of the Warrant Exchange Program, 3,437,072 of these warrants no longer contain the “down round” provision and anti-dilution feature. The warrants affected by the Warrant Exchange Program resulted in a reduction of the warrant liability and an increase in capital in the amount of $4,612,263 after inducement.  The cashless exercise of the 1,160,080 warrants resulted in a reduction of the warrant liability and an increase in capital in the amount of $482,654.
	During 2012,  193,200 warrants at an original exercise price of $1.50 were issued upon partial conversion of the December 14, 2011 Convertible Notes, which include “down round” provisions and resulted in a derivative liability upon issuance of approximately $152,000.  Due to subsequent issuance of common stock and instruments convertible into common stock, and the effects of the Warrant Exchange Program, the number of warrants issuable and their exercise price has been adjusted.  As of December 31, 2013, warrants issued during 2012 related to partial conversion of the December 14, 2011 Convertible Notes now amount to  180,047 warrants outstanding with an exercise price of $1.15 per share.  These outstanding warrants have retained their “down round” provision and anti-dilution feature.  The warrants affected by the Warrant Exchange Program resulted in a reduction of the warrant liability and an increase in capital in the amount of $158,919 after inducement.
	Between January 2, 2013 and February 6, 2013 Convertible Notes issued on December 14, 2011 with a carrying value of $1,408,750 (together with accrued interest) were converted into  2,035,720 shares of common stock and five-year warrants to purchase  2,662,769 shares of common stock at $1.50 per share. The number of warrants issued upon conversion includes  219,909 lock-up warrants with the same rights as the December 14, 2011 Convertible Notes warrants.  These warrants include a “down round” provision and resulted in a derivative liability upon conversion of $1,445,091.  As a result of equity securities issued in 2013 and the effects of the Warrant Exchange Program there are now  802,215 warrants outstanding with an exercise price of $1.38 per share.  As a result of the Warrant Exchange Program these warrants no longer contain their “down round” provision or anti-dilution feature.  The warrants affected by the Warrant Exchange Program resulted in a reduction of the warrant liability and an increase in capital in the amount of $7,637,813 after inducement.
	In May 2012, the Company issued  1,710,833 five-year warrants to purchase common stock in a private placement with an original exercise price of $1.00. These warrants contain a “down round” provision and anti-dilution feature and resulted in a derivative liability upon issuance of approximately $1,841,000. The Company issued  124,217 lock-up warrants to the holders of May 2012 private placement warrants with the same rights as the warrants originally issued. The exercise price of the May 2012 warrants and lock-up warrants was adjusted as a result of subsequent equity securities issued at a lower price than the original exercise price. As a result of the Warrant Exchange Program and the cash exercise of 275,000 warrants during the third quarter of 2013, there remains 974,201 warrants with an exercise price of $0.60 per share outstanding as of December 31, 2013.  As a result of the Warrant Exchange Program these warrants no longer contain their “down round” provision and anti-dilution feature.  The $165,000 cash exercise of the 275,000 warrants resulted in a reduction of the warrant liability and an increase in capital in the amount of $421,817.  The warrants affected by the Warrant Exchange Program resulted in a reduction of the warrant liability and an increase in capital in the amount of $3,013,587.
	Convertible notes issued in August 2012 entitled the holders to at least  185,500 warrants and up to  371,000 warrants (five-year warrants with an exercise price of $1.00 per share), which resulted in a derivative liability of $92,750 recorded at the time the notes were issued.  In connection with the conversion of the August 9, 2012 convertible notes during August 2013, the Company issued  371,000 five-year warrants with an exercise price of $1.00 per share. These warrants include a “down round” provision and resulted in a derivative liability upon conversion of $731,662.  As a result of equity securities issued in 2013 and the effects of the Warrant Exchange Program, there are now  184,047 warrants outstanding with exercise prices of $0.96.  These outstanding warrants have retained their “down round” provision and anti-dilution feature.  The warrants affected by the Warrant Exchange Program resulted in a reduction of the warrant liability and an increase in capital in the amount of $555,165 after inducement.
	In November 2012, the Company issued  1,619,000 five-year warrants to purchase common stock in a private placement with an original exercise price of $1.00. These warrants contain “down round” provision and anti-dilution feature and resulted in a derivative liability upon issuance of $353,747. The Company issued 53,950 lock-up warrants to the holders of November 2012 private placement warrants with the same rights as the warrants originally issued. The exercise price of the November 2012 warrants and lock-up warrants was adjusted as a result of subsequent equity securities issued at a lower price than the original exercise price.  As a result of the Warrant Exchange Program and the cashless exercise of 63,000 warrants in the third quarter of 2013, 1,518,600 warrants with an exercise price of $0.60 per share remain outstanding as of December 31, 2013.  As a result of the Warrant Exchange Program these warrants no longer contain their “down round” provision and anti-dilution feature.  The cashless exercise of the 63,000 warrants resulted in a reduction of the warrant liability and an increase in capital in the amount of $111,468. The warrants affected by the Warrant Exchange Program resulted in a reduction of the warrant liability and an increase in capital in the amount of $3,661,718.
	The Company issued  6,250,000 warrants to purchase common stock in the January 2013 Series A-1 Preferred Stock private placement, including  4,166,666 Series A Warrants, which are five-year warrants with an exercise price of $0.72 per share and  2,083,334 Series B Warrants, which are one-year warrants with an exercise price of $0.60 per share.  These warrants include a “down round” provision and an anti-dilution feature and resulted in a derivative liability upon issuance. The fair value of the Series A Warrants, Series B Warrants and the lock-up warrants issued to the May and November 2012 private placement warrant holders in conjunction with the January 2013 Series A-1 Preferred Stock private placement amounted to $6,022,319.  Further,  2,083,334 Series C Warrants are issuable upon exercise of the Series B Warrants. During June and July of 2013, 982,300 and 1,101,034 Series B Warrants, respectively, were exercised on a cash basis.  The exercise of these Series B Warrants triggered the issuance of a like amount of Series C Warrants totaling 2,083,334 Series C Warrants.  The Series C Warrant shares outstanding are exercisable at $0.72 and include a “down round” provision, which results in a derivative liability upon issuance.  The fair value of the  982,300 Series C Warrant shares issued in June 2013, and the fair value of the  1,101,034 Series C Warrants issued in July 2013, amounted to $711,675 and $1,622,069, respectively.  On August 1, 2013, the Company entered into a Warrant Exercise Agreement (see Note 3 for a more detailed description of the Agreement) with holders of its Series A Warrants and Series C Warrants for such holders to exercise a portion of such Series C Warrants to acquire an aggregate of  1,666,666 shares of the Company’s common stock for a cash payment to the Company of $1,000,000.  In exchange for the cash exercise of such portion of the Series C Warrants, the Company reduced the exercise price of all of the Series A Warrants and Series C Warrants to $0.60 per share. The reduced exercised price resulted in an increase in the warrant liability associated with the Series A Warrants and Series C Warrants and a corresponding reduction in capital in the amount of $626,328.  The Series C Warrant holders exercised the cash option on August 5, 2013.  In addition, between August and December 2013, the Series A and Series C Warrant holders exercised on a cashless basis at $0.60 per share  4,166,666 and  416,668 Series A and Series C Warrants, respectively.  There are no Series A Warrants, Series B Warrants or Series C Warrants outstanding at December 31, 2013.
	The Company estimates the value of warrant liability upon issuance of the warrants and at each balance sheet date using the binomial lattice model to allocate total enterprise value to the warrants and other securities in the Company’s capital structure. Volatility was estimated based on historical observed equity volatilities and implied (forward) or expected volatilities for a sample group of guideline companies and consideration of recent market trends.    The following table is a roll-forward summary of the warrant liability:
	Fair value at December 31, 2011		$	550,000
	Fair value of warrant liability upon partial conversion of December 14, 2011 Notes			152,100
	Fair value of warrant liability upon issuance – May 15, 2012			1,841,000
	Fair value of warrant liability related to minimum warrants issuable upon maturity of			92,750
	August 9, 2012 convertible notes
	Fair value of warrant liability upon issuance – November 9, 2012			353,747
	Loss as a result of change in fair value			1,183,543
	Fair value at December 31, 2012		$	4,173,140
	Fair value of warrant liability upon conversion of remaining December 14, 2011			1,445,091
	Notes -– Q1 2013
	Fair value of warrant liability upon issuance – Q1 2013			6,022,319
	Fair value of warrant liability upon issuance – Q2 2013			711,675
	Fair value of warrant liability upon issuance – Q3 2013			1,622,069
	Fair value of warrant liability upon conversion of August 9, 2012 Notes -– Q3 2013			731,662
	Fair value of warrant liability upon reduction of exercise price of Series A and Series			626,328
	C warrants – Q3 2013
	Reclassification of warrant liability to equity upon exercise of warrants – Q2 2013			-204,513
	Reclassification of warrant liability to equity upon exercise of warrants – Q3 2013			-6,542,904
	Reclassification of warrant liability to equity upon exercise of warrants – Q4 2013			-7,712,170
	Cost of inducement from Warrant Exchange Program – Q4 2013			3,274,313
	Reclassification of warrant liability to equity resulting from Warrant Exchange Program			-19,639,465
	– Q4 2013
	Loss as a result of change in fair value			19,271,977
	Fair value at December 31, 2013		$	3,779,522
	The aggregate net loss as a result of the Company’s warrant liability for the year ended December 31, 2013 amounted to $19,271,977 which is included in other income (expenses) as part of “warrant liability loss - net” in the accompanying consolidated statements of operations.  The loss for the year ended December 31, 2013, also includes a charge to other income (expense) in the amount of $4,330,734, as a result of (i) warrant liabilities issued in connection with the Series A-1 Preferred Stock in excess of net proceeds raised in the amount of $3,987,655 in January 2013, and (ii) warrant liabilities issued in connection with the July 2013 issuance of  1,101,034 Series C Warrants in excess of the sum of the net proceeds received upon exercise and the reclassification of the warrant liability to capital, in the amount of $343,079.  Warrant liabilities issued in connection with the December 14, 2011 Convertible Notes and the August 9, 2012 convertible notes converted to common stock in excess of the conversion amount by $17,386 and $509,062, respectively, were recorded as additional interest expense.
	ASC 820 - “Fair Value Measurements and Disclosures” establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:
		⋅	Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
		⋅	Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
		⋅	Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value.
	A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The warrant liability is measured at fair value using certain estimated factors such as volatility and probability which are classified within Level 3 of the valuation hierarchy.  Significant unobservable inputs are used in the fair value measurement of the Company’s derivative warrant liabilities include volatility.  Significant increases (decreases) in the volatility input would result in a significantly higher (lower) fair value measurement.
	The following table summarizes the warrant activity since December 31, 2011:
			Number of Warrants
	Warrants outstanding at December 31, 2011		8,668,701
	Warrants issued		3,523,033
	Additional warrants due to anti-dilution provisions		780,930
	Warrants exercised during 2012		-
	Warrants outstanding at December 31, 2012		12,972,664
	Warrants issued		11,570,274
	Warrants issued as part of Warrant Exchange Program		138,666
	Additional warrants due to anti-dilution provisions		1,665,400
	Warrants exercised during 2013		-9,831,414
	Warrants exercised as part of Warrant Exchange Program		-5,862,121
	Warrants outstanding at December 31, 2013		10,653,469
	Composition of outstanding warrants:
	Warrants containing anti-dilution feature		3,921,381
	Warrants with anti-dilution feature removed		6,732,088
			10,653,469

RETIREMENT_PLAN

RETIREMENT PLAN	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure	'
	NOTE 11. - RETIREMENT PLAN
	The Company sponsors a defined contribution plan under IRC Section 401(k).  The plan covers all employees who meet the minimum eligibility requirements.  Under the 401(k) plan eligible employees are allowed to made voluntary deferred salary contribution to the plan, subject to statutory limits.  The Company has elected to make Safe Harbor Non-elective Contributions to the plan for eligible employees in the amount of three percent (3%) of the employee’s compensation.  Total employer contributions to the plan, including a contribution made for 2012 in the first quarter of 2013, amounted to $34,873 for the year ended December 31, 2013.  There were no employer contributions to the plan for the year ended December 31, 2012.

COMMITMENTS

COMMITMENTS	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS	'
	NOTE 12. - COMMITMENTS
	License Agreements - Under its exclusive license agreement with North Carolina State University (“NCSU”), the Company is required to pay minimum annual royalty payments, which are credited against running royalties on sales of licensed products. The annual minimum royalty for 2013 is $75,000, and in 2016 the annual minimum royalty increases to $225,000.  The license agreement continues through the life of the last-to-expire patent, which is expected to be 2022. The agreement also requires a milestone payment of $150,000 upon FDA approval or clearance of a product that uses the NCSU licensed technology. The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred. These costs vary from year to year and the Company has certain rights to direct the activities that result in these costs. During the year ended December 31, 2013, the costs incurred related to patent costs and patent maintenance amounted to $101,902 ($104,558 during the year ended December 31, 2012).
	The Company has two other exclusive license agreements which require aggregate annual license fees of approximately $75,000, which are credited against running royalties on sales of licensed products. Each license agreement continues through the life of the last-to-expire patent.
	Membership Interest Purchase Agreement  – On September 17, 2013, the Company entered into a Membership Interest Purchase Agreement (“Purchase Agreement”) to purchase all of the issued and outstanding membership interests of NASCO Products, LLC, (“NASCO”), a North Carolina limited liability company (the “NASCO Transaction”).  NASCO is a federally licensed tobacco product manufacturer and a participating member of the Tobacco Master Settlement Agreement known as the MSA, an agreement among 46 U.S. states and the tobacco industry administered by the National Association of Attorneys General (“NAAG”).
	The initial purchase price for the NASCO Transaction is One Million Dollars ($1,000,000) (the “Purchase Price”), subject to potential closing date adjustments for any unpaid liabilities of NASCO.  The Purchase Price will be paid as follows:  (i) a cash payment of Two Hundred Thousand ($200,000) and (ii) the issuance of Eight Hundred Thousand Dollars ($800,000) in value of unregistered shares of common stock of the Company based on the average of the five (5) day closing price of the Company’s common shares on the OTCBB for the five (5) trading days immediately preceding the closing date.  In no event shall the number of common shares issued by the Company to NASCO be less than  640,000 or greater than 1,066,667.
	The Purchase Agreement contains customary representatives, warranties, covenants and indemnities.  Consummation of the NASCO Transaction is subject to various conditions, including receipt of material third party consents and approvals and other customary closing conditions, including required consents from NAAG and certain attorneys general of the settling states of the MSA.  NAAG has been discussing the NASCO Transaction with a small working group of settling states of the MSA in which the Company has answered various rounds of questions from.  The working group has presented the matter to all the settling states with a recommended course of action which is being evaluated by the settling states.  Upon the entry of a revised adherence agreement of NASCO Products, LLC reflecting the NASCO Transaction, the Company believes it will be able to close the NASCO Transaction.  The Purchase Agreement contains termination rights, including a right for the Company to terminate the Purchase Agreement, solely up to the Company’s discretion, if the closing shall not have occurred on or before January 31, 2014.  The Purchase Agreement also contemplates that the Company will enter into a management agreement and sales representation agreement at closing with an affiliate of NASCO.
	Lease Agreements  - On October 9, 2013, the Company executed a guaranty that guarantees performance by NASCO of its obligations to the landlord under a certain triple net lease of the same date between NASCO and the landlord for a warehouse and cigarette manufacturing facility located in North Carolina.  Should the Purchase Agreement close as discussed earlier, NASCO will become a wholly owned subsidiary of the Company, making the lease a direct obligation of the Company.  The lease commenced on January 14, 2014, and has an initial term of twelve (12) months (the “Initial Term”).  The lease contains four (4) additional extensions; one for an additional one (1) year and three for an additional two (2) years  in duration, exercisable at the option of NASCO.  The lease also contains an early termination clause that provides NASCO with the right to terminate the lease at any time during the first nine (9) month of the Initial Term by giving ninety (90) days prior written notice to the landlord.  The lease calls for minimum lease payments of $96,000, $123,000, $298,275, $338,250 and $338,250 during the Initial Term, the one (1) year optional extension, and each of the three (3), two (2) year optional extensions, respectively. These commitments are not included in the schedule below.
	The Company entered into a three year lease for office space in Clarence, New York, which commenced September 1, 2011.  On January 25, 2013, the Company entered into a two and a half year lease for manufacturing space in Depew, New York, which commenced February 1, 2013.   Scheduled rent commitments remaining as of December 31, 2013 are approximately as follows:
	2014	$	45,000
	2015	$	10,000
	Limited Market Make-Good Provision  – The Company has a contingent obligation to make whole, through a cash payment, shareholders who exercised the Series C Warrants on August 1, 2013, if the holders incur a loss on the sale of common stock received. (See Note 3 for a detailed discussion).

EARNINGS_PER_COMMON_SHARE

EARNINGS PER COMMON SHARE	12 Months Ended
	Dec. 31, 2013
Earnings Per Common Share [Abstract]	'
EARNINGS PER COMMON SHARE	'
	NOTE 13. - EARNINGS PER COMMON SHARE
	The following table sets forth the computation of basic and diluted earnings per common share for the year ended December 31, 2013 and 2012:
		December 31,		December 31,
		2013		2012
	Net loss attributed to common shareholders	$	-26,153,158	$	-6,735,281
	Denominator for basic earnings per share-weighted average		43,635,182		30,419,556
	shares outstanding
	Effect of dilutive securities:
	Warrants, restricted stock and options outstanding		-		-
	Denominator for diluted earnings per common share - weighted		43,635,182		30,419,556
	average shares adjusted for dilutive securities
	Loss per common share - basic	$	-0.6	$	-0.22
	Loss per common share- diluted	$	-0.6	$	-0.22
	Securities outstanding that were excluded from the computation of earnings per share for the year ended December 31, 2013 and 2012 because they would have been anti-dilutive are as follows:
		December 31,		December 31,
		2013		2012
	Warrants		10,653,469		12,972,664
	Convertible Debt Issued December 14, 2011 (number of shares		-		4,706,782
	including related warrants upon conversion of 3,061,034)
	Convertible Debt Issued August 9, 2012 (number of shares including		-		742,000
	related warrants upon conversion of 371,000)
	Restricted Stock		500,000		550,000
	Options		660,000		465,000
			11,813,469		19,436,446

STOCK_BASED_COMPENSATION

STOCK BASED COMPENSATION	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK BASED COMPENSATION	'
	NOTE 14. - STOCK BASED COMPENSATION
	On October 21, 2010, the Company established the 2010 Equity Incentive Plan (“EIP”) for officers, employees, directors, consultants and advisors to the Company and its affiliates, consisting of 4,250,000 shares of common stock.  The EIP has a term of ten years and is administered by our Board of Directors (“Board”) or a committee to be established by our Board (the “Administrator”), to determine the various types of incentive awards that may be granted to recipients under this plan and the number of shares of common stock to underlie each such award under the EIP.  On March 30, 2011, the Company filed a Form S-8 registration statement with the SEC to register all of the shares of common stock of 22nd Century Group that it may issue under the EIP.
	For year ended December 31, 2013, the Company recorded compensation expense related to restricted stock and stock option awards granted under the EIP of $998,214 ($732,209 for the year ended December 31, 2012).  The Company also recorded stock based compensation for the year ended December 31, 2013, through the issuance of 1,780,000 shares of the Company’s common stock, as payment to third parties for services rendered in the amount of $1,363,748 ($521,962 for the year ended December 31, 2012).
	During the year ended December 31, 2013, the Company issued restricted stock awards from the EIP for 890,000 restricted shares to employees and directors that vested immediately on February 25, 2013 and for 100,000 restricted shares that will vest one year from the April 1, 2013 grant date.   Further, 150,000 shares of a restricted stock award previously granted from the EIP vested during the period. All awards were valued at the closing price on the measurement date of the award.
	As of December 31, 2013, unrecognized compensation expense related to non-vested restricted shares and stock options amounted to approximately $100,000, which is expected to be recognized over the next two years.
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were used for the years ended December 31, 2013 and 2012:
		2013			2012
	Risk-free interest rate	1.89	%		1.71	%
	Expected dividend yield	0	%		0	%
	Expected stock price volatility	90	%		90	%
	Expected life of options	10 years			10 years
	The Company estimated the expected volatility based on data used by peer group of public companies. The expected term was estimated using the contract life of the option. The risk-free interest rate assumption was determined using yield of the equivalent U.S. Treasury bonds over the expected term. The Company has never paid any cash dividends and does not anticipate paying any cash dividends in the foreseeable future. Therefore, the Company assumed an expected dividend yield of zero.
	A summary of all stock option activity since December 31, 2011 is as follows:
							Weighted
					Weighted		Average
		Number			Average		Remaining		Aggregate
		of			Exercise		Contractual		Intrinsic
		Options			Price		Term		Value
	Outstanding at December 31, 2011	35,000		$	1.2
	Granted in 2012	455,000		$	0.65
	Forfeited in 2012	-25,000		$	0.69
	Outstanding at December 31, 2012	465,000		$	0.69
	Granted in 2013	215,000		$	0.8
	Exercised in 2013	-20,000		$	0.26
	Outstanding at December 31, 2013	660,000		$	0.74		8.6 years	$	923,500
	Exercisable at December 31, 2013	660,000		$	0.74		8.6 years	$	923,500
	The weighted average grant date fair value of options issued in 2013 was $0.68 ($0.56 – 2012).  The total fair value of option that vested during 2013 amounted to $186,959 ($242,160 – 2011). During the year ended December 31, 2013, 20,000 options were exercised for cash proceeds of $5,200. No options were exercised during the year ended December 31, 2012.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 15. - INCOME TAXES
	The following is a summary of the components giving rise to the income tax provision (benefit) for the years ended December 31, 2013 and 2012.
	The provision (benefit) for income taxes consists of the following:
			2013		2012
	Current:
	Federal	$	-	$	-
	State		-		-
	Total current		-		-
	Deferred:
	Federal		829,306		-1,370,382
	State		186,414		-308,039
	Total deferred		1,015,720		-1,678,421
	Change in valuation allowance		-1,015,720		1,678,421
		$	-	$	-
	The provision (benefit) for income tax varies from that which would be expected based on applying the statutory federal rate to pre-tax accounting loss as follows:
		2013		2012
	Statutory federal rate	-34	%	-34	%
	Permanent items	1.8		2
	Derivative liability	35.5		10.1
	State tax provision, net of federal benefit	0.5		-3
	Valuation allowance	-3.9		24.9
	Effective tax rate (benefit) provision	0	%	0	%
	Individual components of deferred taxes consist of the following:
			2013		2012
	Deferred tax assets:
	Net operating loss carry-forward	$	2,616,624	$	3,694,817
	Derivative liability		21,725		21,725
	Inventory reserve		19,584		69,120
	Stock-based compensation		131,450		-
	Other		1,292		967
			2,790,675		3,776,629
	Deferred tax liabilities:
	Inventory		-52,445		-
	Fixed assets		-2,956		-2,333
	Patents and trademarks		-523,157		-490,882
	Stock-based compensation		-		-28,300
	Beneficial conversion feature of convertible debt		-		-27,277
			-578,558		-548,792
	Valuation allowance		-2,212,117		-3,227,837
	Net deferred taxes	$	-	$	-
	The Company has incurred a net operating loss of approximately $6,800,000 through December 31, 2013 and this amount is being carried forward to future years and expires in 2031 and 2032. Due to the uncertainty of the Company’s ability to generate sufficient taxable income in the future before they expire, the company has recorded a valuation allowance to reduce the net deferred tax asset to zero. This NOL is included in the net deferred tax asset that has been fully offset by the valuation allowance.
	ASC 740 provides guidance on the financial statement recognition and measurement for uncertain income tax positions that are taken or expected to be taken in a company’s income tax return.  The Company has no uncertain tax positions as of December 31, 2013.
	The Company’s federal and state tax returns for the years ended September 30, 2011 to December 31, 2012 are currently open to audit under the statutes of limitations. There are no pending audits as of December 31, 2013.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENT	'
	NOTE 16. - SUBSEQUENT EVENTS
	Effective January 27, 2014, the Company’s board of directors awarded officers, employees and directors an aggregate of 850,000 restricted shares that vest one year from the effective date.

NATURE_OF_BUSINESS_AND_SUMMARY1

NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation- The accompanying consolidated financial statements include the accounts of 22nd Century Group, its wholly owned subsidiary, 22nd Century Ltd, and 22nd Century Ltd’s wholly owned subsidiaries, Goodrich Tobacco Company, LLC (“Goodrich Tobacco”) and Hercules Pharmaceuticals, LLC (“Hercules Pharma”) (collectively, “the Company”). In May 2012, 22nd Century Ltd acquired from an employee the non-controlling membership units of Goodrich Tobacco that it did not own so that Goodrich Tobacco became a wholly owned subsidiary. All intercompany accounts and transactions have been eliminated.
Nature of Business	'
	Nature of Business- 22nd Century Ltd, is a plant biotechnology company specializing in technology that allows for the level of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The Company owns or exclusively controls 114 issued patents in 78 countries plus an additional 38 pending patent applications.  Goodrich Tobacco and Hercules Pharma are business units for the Company’s (i) premium cigarettes and potential modified risk tobacco products and (ii) smoking cessation product, respectively.
Reclassifications	'
	Reclassifications- Certain items in the 2012 financial statements have been reclassified to conform to the 2013 classification.
Preferred stock authorized	'
	Preferred Stock Authorized- the authorization is for “blank check” preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock. On January 11, 2013 the Company designated the rights of and issued 2,500 shares of Series A-1 Preferred Stock.  As of June 7, 2013, all 2,500 outstanding shares of Series A-1 Preferred Stock were converted into an aggregate 4,166,666 shares of common stock of the Company (see Note 3) and no shares of preferred stock remain outstanding.
Inventory	'
	Inventory - Inventories are valued at the lower of cost or market. Cost is determined on the first-in, first-out (FIFO) method.  Inventories are evaluated to determine whether any amounts are not recoverable based on slow moving or obsolete condition and are written off or reserved as appropriate. As of December 31, 2013 and 2012, the Company’s inventory consisted primarily of raw materials, mainly tobacco.
Fixed assets	'
	Fixed assets – Fixed assets are recorded at their acquisition cost and depreciated on a straight line basis over their estimated useful lives ranging from 5 to 10 years.  Depreciation commences when the asset is placed in service.  Cigarette manufacturing equipment purchased in December 2013 in the amount of  $2,762,304 was not placed in service at December 31, 2013 and accordingly, no depreciation was taken.  Certain cigarette manufacturing equipment with a cost of $457,696 will not be used in the Company’s operations and has been recorded as “Machinery and equipment held for resale” on the Company’s Balance Sheet at December 31, 2013.
Intangible Assets	'
	Intangible Assets - Intangible assets are recorded at cost and consist primarily of expenditures incurred with third parties related to the processing of patent claims and trademarks with government authorities, as well as costs to acquire patent rights from third parties. The amounts capitalized relate to intellectual property that the Company owns or to which it has exclusive rights. The Company’s intellectual property capitalized costs are amortized using the straight-line method over the remaining statutory life of the primary patent in each of the Company’s two largest patent families, which expires in 2019 and 2028 (the assets’ estimated lives). Periodic maintenance or renewal fees are expensed as incurred.  Annual minimum license fees are charged to expense. Total patent and trademark costs capitalized at December 31, 2013 and 2012 consist of the following:
	During the year ended December 31, 2013, the Company changed the estimated useful life of one of the patent families. The change did not have a material impact on the financial statements.
			December 31,		December 31,
			2013		2012
	Patent and trademark costs	$	2,559,412	$	2,226,586
	Less: accumulated amortization		1,014,543		873,282
	Patent and trademark costs, net	$	1,544,869	$	1,353,304
	The estimated annual amortization expense for the next five years is approximately $177,000.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets  - The Company reviews the carrying value of its amortizing long-lived assets whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may no longer be recoverable. The Company assesses recoverability of the asset by estimating the future undiscounted net cash flows expected to result from the asset, including eventual disposition. If the estimated future undiscounted net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and its fair value. There was no impairment loss recorded during the year ended December 31, 2013 or 2012.
Income Taxes	'
	Income Taxes - The Company recognizes deferred tax assets and liabilities for any basis differences in its assets and liabilities between tax and GAAP reporting, and for operating loss and credit carry-forwards.
	In light of the Company’s history of cumulative net operating losses and the uncertainty of their future utilization, the Company has established a valuation allowance to fully offset its net deferred tax assets as of December 31, 2013 and 2012.
	The Company’s federal and state tax returns for the years ended September 30, 2011 to December 31, 2012 are currently open to audit under the statutes of limitations.  There are no pending audits as of December 31, 2013.
Refundable taxes and tax credits	'
	Refundable taxes and tax credits – The Company accounts for income tax refunds or tax refundable tax credits as discrete items and recognized the amount in the period in which the funds are received. During the year ended December 31, 2013, the Company received notice from the New York State Department of Taxation and Finance of a no change audit with respect to its income tax return filed for the period ending September 30, 2011. The subject return contained a refundable credit in the amount of $122,000.  The refund was recorded as other income in the Company’s consolidated statement of operations. There were no such transactions during the year ended December 31, 2012.
Stock Based Compensation	'
	Stock Based Compensation - The Company uses a fair-value based method to determine compensation for all arrangements under which Company employees and others receive shares, options or warrants to purchase common shares of 22nd Century Group. Stock based compensation expense is recorded over the requisite service period based on estimates of probability and time of achieving milestones and vesting. For accounting purposes, the shares will be considered issued and outstanding upon vesting.
Debt Discounts	'
	Debt Discounts - Original issue discount (“OID”) is recorded equal to the difference between the cash proceeds, after allocation to warrants issued or issuable upon payment of the debt, and the face value of the debt when issued and amortized as interest expense during the term of the debt.
	When the convertible feature of the conventional convertible debt is issued, the embedded conversion feature is evaluated to determine if bifurcation and derivative treatment is required and whether there is a beneficial conversion feature.  When the convertible debt provides for an effective rate of conversion that is below market value, this feature is characterized as a beneficial conversion feature (“BCF"). Prior to the determination of the BCF, the proceeds from the debt instrument were first allocated between the convertible debt and any embedded or detachable free standing instruments that are included, such as common stock warrants. The proceeds allocated to any warrants are recorded as a debt discount.
	The debt discount is amortized to interest expense over the life of the debt. In the case of any conversion prior to the maturity date there will be an unamortized amount of debt discount that relates to such conversion.  The pro rata amount of unamortized discount at the time of such conversion is charged to interest expense as accelerated amortization of the discount.  The fair value of warrants issued at the time of conversion is recorded as a reduction of the amount applied to the common stock issued in the conversion and to the extent that the fair value of warrants exceeds the carrying value of the debt a charge to interest expense results for such excess amount.
Revenue Recognition	'
	Revenue Recognition - The Company recognizes revenue from product sales at the point the product is shipped to a customer and title has transferred.  Revenue from the sale of the Company’s products is recognized net of cash discounts, sales returns and allowances. Cigarette federal excise taxes are included in net sales and accounts receivable billed to customers, except on sales of SPECTRUM research cigarettes and exported cigarettes in which such taxes do not apply.
	The Company was chosen to be a subcontractor for a 5-year government contract between RTI International (“RTI”) and the National Institute on Drug Abuse (“NIDA”) to supply NIDA research cigarettes. These government research cigarettes are distributed under the Company’s mark, SPECTRUM. The Company delivered approximately 12 million SPECTRUM research cigarettes during the year ended December 31, 2012 and 2011 and recognized the related revenue of approximately $807,000. There were no SPECTRUM cigarettes delivered during the year ended December 31, 2013.  Future revenue under this arrangement is expected to be related to the delivery of SPECTRUM and will be recognized at the point the product is shipped and title has transferred.  In September 2013, the Company received a purchase order for an additional 5.5 million SPECTRUM research cigarettes that will be manufactured and shipped in January 2014.  Total revenue from this order will be approximately $448,000 and a down payment on the order was received in the fourth quarter of 2013 in the amount of $179,014.  The down payment has been recorded as deferred revenue on the Company’s balance sheet at December 31, 2013.
	The Company licenses its patented technology to third parties.  Revenue is recognized from licensing arrangements as contractually defined in licensing agreements. The Company accounts for milestones elements contained in licensing agreements in accordance with ASC 605. On October 1, 2013, 22nd Century Ltd entered into a worldwide Research License and Commercial Option Agreement (the “Agreement”) with British American Tobacco (Investments) Limited (“BAT”), a subsidiary of British American Tobacco plc, that grants BAT access to 22nd Century Ltd’s patented technology which alters levels of nicotinic alkaloids in tobacco plants.  Simultaneous with the signing of the Agreement, BAT paid the Company a non-refundable $7,000,000.  The Company will be entitled to receive additional payments from BAT of up to an additional $7,000,000 during the term of the Research License in the event certain milestones are met by BAT with respect to its research and development of the patent rights and licensed intellectual property rights licensed by the Company to BAT. No amount related to the additional research milestones were recognized during 2013. During the term of the Research License, BAT will have the option to enter into a Commercial License agreement which will provide for future royalty payments based on sales.  A portion of the patented technology sublicensed to BAT is exclusively licensed to 22nd Century Ltd by a third party licensor. Pursuant to the terms of the license agreement with such licensor, 22nd Century Ltd is obligated to make a royalty payment to the licensor. 22nd Century Ltd estimates the payment to be approximately  $414,000, subject to the mutual agreement of 22nd Century Ltd and the third party licensor.
Derivatives	'
	Derivatives - We do not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and then is revalued at each reporting date, with changes in fair value reported in the consolidated statement of operations.  The methodology for valuing our outstanding warrants classified as derivative instruments utilizes a lattice model approach which includes probability weighted estimates of future events including volatility of our common stock. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.
Research and Development	'
	Research and Development -Research and development costs are expensed as incurred.
Loss Per Common Share	'
	Loss Per Common Share - Basic loss per common share is computed using the weighted-average number of common shares outstanding.  Diluted loss per share is computed assuming conversion of all potentially dilutive securities. Potential common shares outstanding are excluded from the computation if their effect is anti-dilutive.
Commitment and Contingency Accounting	'
	Commitment and Contingency Accounting - The Company evaluates each commitment and/or contingency in accordance with the accounting standards, which state that if the item is more likely than not to become a direct liability, then the Company will record the liability in the financial statements. If not, the Company will disclose any material commitments or contingencies that may arise.
Use of Estimates	'
	Use of Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.
Fair value of financial instruments	'
	Fair Value of Financial Instruments -  Financial instruments include cash, receivables, accounts payable, accrued expenses, notes payable, demand bank loan, convertible notes payable and warrant liability.  Other than warrant liability and convertible notes payable, fair value is assumed to approximate carrying values for these financial instruments, since they are short term in nature, they are receivable or payable on demand, or had stated interest rates that approximate the interest rates available to the Company as of the reporting date.  The determination of the fair value of the warrant liability includes unobservable inputs and is therefore categorized as a Level 3 measurement, as further discussed in Note 10.  There are no convertible notes outstanding at December 31, 2013.

NATURE_OF_BUSINESS_AND_SUMMARY2

NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	During the year ended December 31, 2013, the Company changed the estimated useful life of one of the patent families. The change did not have a material impact on the financial statements.
			December 31,		December 31,
			2013		2012
	Patent and trademark costs	$	2,559,412	$	2,226,586
	Less: accumulated amortization		1,014,543		873,282
	Patent and trademark costs, net	$	1,544,869	$	1,353,304

MACHINERY_AND_EQUIPMENT_Tables

MACHINERY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
MACHINERY AND EQUIPMENT	'
	Machinery and equipment at December 31, 2013 and 2012 consists of the following:
		December 31,		December 31,
		2013		2012
	Cigarette manufacturing equipment	$	3,220,000	$	-
	Office furniture, fixtures and equipment		17,059		9,106
	Leasehold improvements		14,500		-
	Deposit for purchase of machine parts and other assets		210,000		-
			3,461,559		9,106
	Less: cigarette manufacturing equipment held for resale		457,696		-
			3,003,863		9,106
	Less: accumulated depreciation		6,103		3,076
	Machinery and equipment, net	$	2,997,760	$	6,030

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Notes Payable	'
	Notes payable consisted of the following as of the dates set forth below:
			December 31,		December 31,
			2013		2012
	Note dated March 31, 2011	$	-	$	77,000
	Note dated January 25, 2011		-		140,000
	Note dated March 13, 2013 and March 30, 2011		-		350,000
	Note dated March 22, 2012 and April 13, 2012		-		50,000
	Note dated January 15, 2013		-		-
	Note dated January 23, 2013		-		-
	Note dated January 24, 2013		-		-
	Note dated February 1, 2013		-		-
	Notes payable	$	-	$	617,000

CONVERTIBLE_NOTES_Tables

CONVERTIBLE NOTES (Tables)	12 Months Ended
	Dec. 31, 2013
Convertible Notes [Abstract]	'
Summary of Notes and Related Discount	'
	The following table summarizes convertible notes and related discount.
		December 31,		December 31,
		2013		2012
	Face value of all convertible notes payable through maturity	$	-	$	2,028,100
	Less unamortized original issue discount		-		-63,787
	Less unamortized discount related to BCF		-		-70,509
	Convertible Notes, net of unamortized debt discount	$	-	$	1,893,804
	Carrying value of December 14, 2011 Convertible Notes	$	-	$	1,805,500
	Carrying value of August 9, 2012 Convertible Notes	$	-	$	88,304

WARRANT_EXCHANGE_PROGRAM_AND_W1

WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Tables)	12 Months Ended
	Dec. 31, 2013
Warrants For Common Stock [Abstract]	'
Roll-Forward of Warrant Liability from Intitial Valuation	'
	The following table is a roll-forward summary of the warrant liability:
	Fair value at December 31, 2011	$	550,000
	Fair value of warrant liability upon partial conversion of December 14, 2011 Notes		152,100
	Fair value of warrant liability upon issuance – May 15, 2012		1,841,000
	Fair value of warrant liability related to minimum warrants issuable upon maturity of		92,750
	August 9, 2012 convertible notes
	Fair value of warrant liability upon issuance – November 9, 2012		353,747
	Loss as a result of change in fair value		1,183,543
	Fair value at December 31, 2012	$	4,173,140
	Fair value of warrant liability upon conversion of remaining December 14, 2011		1,445,091
	Notes -– Q1 2013
	Fair value of warrant liability upon issuance – Q1 2013		6,022,319
	Fair value of warrant liability upon issuance – Q2 2013		711,675
	Fair value of warrant liability upon issuance – Q3 2013		1,622,069
	Fair value of warrant liability upon conversion of August 9, 2012 Notes -– Q3 2013		731,662
	Fair value of warrant liability upon reduction of exercise price of Series A and Series		626,328
	C warrants – Q3 2013
	Reclassification of warrant liability to equity upon exercise of warrants – Q2 2013		-204,513
	Reclassification of warrant liability to equity upon exercise of warrants – Q3 2013		-6,542,904
	Reclassification of warrant liability to equity upon exercise of warrants – Q4 2013		-7,712,170
	Cost of inducement from Warrant Exchange Program – Q4 2013		3,274,313
	Reclassification of warrant liability to equity resulting from Warrant Exchange Program		-19,639,465
	– Q4 2013
	Loss as a result of change in fair value		19,271,977
	Fair value at December 31, 2013	$	3,779,522
Warrant Activity	'
	The following table summarizes the warrant activity since December 31, 2011:
		Number of Warrants
	Warrants outstanding at December 31, 2011	8,668,701
	Warrants issued	3,523,033
	Additional warrants due to anti-dilution provisions	780,930
	Warrants exercised during 2012	-
	Warrants outstanding at December 31, 2012	12,972,664
	Warrants issued	11,570,274
	Warrants issued as part of Warrant Exchange Program	138,666
	Additional warrants due to anti-dilution provisions	1,665,400
	Warrants exercised during 2013	-9,831,414
	Warrants exercised as part of Warrant Exchange Program	-5,862,121
	Warrants outstanding at December 31, 2013	10,653,469
	Composition of outstanding warrants:
	Warrants containing anti-dilution feature	3,921,381
	Warrants with anti-dilution feature removed	6,732,088
		10,653,469

COMMITMENTS_Tables

COMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Scheduled Rent	'
	Scheduled rent commitments remaining as of December 31, 2013 are approximately as follows:
	2014	$	45,000
	2015	$	10,000

EARNINGS_PER_COMMON_SHARE_Tabl

EARNINGS PER COMMON SHARE (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Common Share [Abstract]	'
Computation of Basic and Diluted Earnings Per Common Share	'
	The following table sets forth the computation of basic and diluted earnings per common share for the year ended December 31, 2013 and 2012:
		December 31,		December 31,
		2013		2012
	Net loss attributed to common shareholders	$	-26,153,158	$	-6,735,281
	Denominator for basic earnings per share-weighted average		43,635,182		30,419,556
	shares outstanding
	Effect of dilutive securities:
	Warrants, restricted stock and options outstanding		-		-
	Denominator for diluted earnings per common share - weighted		43,635,182		30,419,556
	average shares adjusted for dilutive securities
	Loss per common share - basic	$	-0.6	$	-0.22
	Loss per common share- diluted	$	-0.6	$	-0.22
Schedule Outstanding Excluded from Computation Because they would have bee Anti-dilutive	'
	Securities outstanding that were excluded from the computation of earnings per share for the year ended December 31, 2013 and 2012 because they would have been anti-dilutive are as follows:
		December 31,		December 31,
		2013		2012
	Warrants		10,653,469		12,972,664
	Convertible Debt Issued December 14, 2011 (number of shares		-		4,706,782
	including related warrants upon conversion of 3,061,034)
	Convertible Debt Issued August 9, 2012 (number of shares including		-		742,000
	related warrants upon conversion of 371,000)
	Restricted Stock		500,000		550,000
	Options		660,000		465,000
			11,813,469		19,436,446

STOCK_BASED_COMPENSATION_Table

STOCK BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Fair Value Assumptions	'
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were used for the years ended December 31, 2013 and 2012:
		2013			2012
	Risk-free interest rate	1.89	%		1.71	%
	Expected dividend yield	0	%		0	%
	Expected stock price volatility	90	%		90	%
	Expected life of options	10 years			10 years
Summary of All Stock Option Activity	'
	A summary of all stock option activity since December 31, 2011 is as follows:
							Weighted
					Weighted		Average
		Number			Average		Remaining		Aggregate
		of			Exercise		Contractual		Intrinsic
		Options			Price		Term		Value
	Outstanding at December 31, 2011	35,000		$	1.2
	Granted in 2012	455,000		$	0.65
	Forfeited in 2012	-25,000		$	0.69
	Outstanding at December 31, 2012	465,000		$	0.69
	Granted in 2013	215,000		$	0.8
	Exercised in 2013	-20,000		$	0.26
	Outstanding at December 31, 2013	660,000		$	0.74		8.6 years	$	923,500
	Exercisable at December 31, 2013	660,000		$	0.74		8.6 years	$	923,500

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Provision (Benefit) for Income Taxes	'
	The provision (benefit) for income taxes consists of the following:
			2013		2012
	Current:
	Federal	$	-	$	-
	State		-		-
	Total current		-		-
	Deferred:
	Federal		829,306		-1,370,382
	State		186,414		-308,039
	Total deferred		1,015,720		-1,678,421
	Change in valuation allowance		-1,015,720		1,678,421
		$	-	$	-
Schedule of Reconciliation of Income Taxes	'
	The provision (benefit) for income tax varies from that which would be expected based on applying the statutory federal rate to pre-tax accounting loss as follows:
		2013		2012
	Statutory federal rate	-34	%	-34	%
	Permanent items	1.8		2
	Derivative liability	35.5		10.1
	State tax provision, net of federal benefit	0.5		-3
	Valuation allowance	-3.9		24.9
	Effective tax rate (benefit) provision	0	%	0	%
Schedule of Deferred Tax Assets and Liabilities	'
	Individual components of deferred taxes consist of the following:
			2013		2012
	Deferred tax assets:
	Net operating loss carry-forward	$	2,616,624	$	3,694,817
	Derivative liability		21,725		21,725
	Inventory reserve		19,584		69,120
	Stock-based compensation		131,450		-
	Other		1,292		967
			2,790,675		3,776,629
	Deferred tax liabilities:
	Inventory		-52,445		-
	Fixed assets		-2,956		-2,333
	Patents and trademarks		-523,157		-490,882
	Stock-based compensation		-		-28,300
	Beneficial conversion feature of convertible debt		-		-27,277
			-578,558		-548,792
	Valuation allowance		-2,212,117		-3,227,837
	Net deferred taxes	$	-	$	-

NATURE_OF_BUSINESS_AND_SUMMARY3

NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 07, 2013

Dec. 31, 2013

Jun. 07, 2013

Jan. 11, 2013

Number

Number

Cigarete Manufacturing Equipment [Member]

Third Party Licensor [Member]

Maximum [Member]

Minimum [Member]

SPECTRUM Order [Member]

Subsequent Event [Member]

Common Stock [Member]

Series A [Member]

Series A [Member]

Series A [Member]

SPECTRUM Order [Member]

Preferred stock, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

2,500

Preferred Stock, Shares Outstanding

'

'

'

'

'

'

'

'

'

'

'

2,500

'

Number of cigarettes delivered

'

12,000,000

12,000,000

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Issued Upon Conversion

'

'

'

'

'

'

'

'

'

4,166,666

6,250,000

'

'

Revenue Other Manufactured Products

'

'

'

'

'

'

'

$5,500,000

$448,000

'

'

'

'

Contracts Revenue

807,000

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Estimated Useful Lives

'

'

'

'

'

'10

'5

'

'

'

'

'

'

Assets Held-for-sale, Current, Total

457,696

0

'

'

'

'

'

'

'

'

'

'

'

Refundable Taxes And Tax Credits

122,000

0

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Amortization Expense, after Year Five

177,000

'

'

'

'

'

'

'

'

'

'

'

'

Licenses Revenue

7,000,000

0

'

'

'

'

'

'

'

'

'

'

'

Deferred Revenue, Revenue Recognized

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

License Costs

413,566

0

'

'

414,000

'

'

'

'

'

'

'

'

Deferred Revenue

179,014

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Additions

'

'

'

$2,762,304

'

'

'

'

'

'

'

'

'

NATURE_OF_BUSINESS_AND_SUMMARY4

NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Patent and trademark costs	$2,559,412	$2,226,586
Less: accumulated amortization	1,014,543	873,282
Patent and trademark costs, net	$1,544,869	$1,353,304

FINANCIAL_CONDITION_Narrative_

FINANCIAL CONDITION (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Assets, Current, Total	$7,744,115	$1,281,305
Liabilities, Current, Total	984,334	4,602,948
Working Capital	6,759,781	'
Cash and Cash Equivalents, at Carrying Value, Total	5,830,599	'
Equity Method Investments	7,529,000	'
Licenses Revenue	$7,000,000	$0
Description On Issuance Of Financial Services Obligations	'the Company believes it will have adequate cash reserves to sustain operations and meet all current obligations as they come due for a period in excess of 12 months.	'

JANUARY_2013_PREFERRED_STOCK_P1

JANUARY 2013 PREFERRED STOCK PRIVATE PLACEMENT (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Aug. 31, 2013

Jan. 31, 2013

Nov. 30, 2012

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Aug. 06, 2013

Jun. 30, 2013

Dec. 31, 2011

Dec. 31, 2013

Jul. 12, 2013

Dec. 31, 2012

Dec. 31, 2013

Aug. 31, 2013

Dec. 26, 2013

Dec. 31, 2013

Aug. 09, 2012

Nov. 30, 2012

Dec. 31, 2013

Dec. 31, 2013

Jan. 31, 2013

Dec. 31, 2013

Jan. 11, 2013

Dec. 31, 2013

Sep. 20, 2013

Aug. 31, 2013

Aug. 06, 2013

Feb. 06, 2013

Jun. 30, 2013

Dec. 31, 2013

Aug. 31, 2013

Dec. 31, 2013

Aug. 06, 2013

Jun. 30, 2013

Aug. 31, 2013

Aug. 31, 2013

Chardan Capital Markets, LLC [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Series A One Preferred Stock [Member]

Series A One Preferred Stock [Member]

Series A One Preferred Stock [Member]

Series A Warrant [Member]

Series A Warrant [Member]

Series A Warrant [Member]

Series A Warrant [Member]

Series A Warrant [Member]

Series B Warrant [Member]

Series B Warrant [Member]

Series C Warrant [Member]

Series C Warrant [Member]

Series C Warrant [Member]

Series C Warrant [Member]

Series C Warrant [Member]

Series C Warrant [Member]

Chardan Capital Markets, LLC [Member]

Chardan Capital Markets, LLC [Member]

Minimum [Member]

Maximum [Member]

Subsidiary, Sale of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale Of Newly Created Shares For Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Sale Of Newly Created Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale Of Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from sale of preferred shares and convertible notes

'

2,035,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,166,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Conversion Basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'0.60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

'

'

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Annual Cash Dividend

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Additional Conversion Price

'

'

'

'

4,166,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,166,666

'

'

'

'

'

2,083,334

'

2,083,334

'

'

'

'

Common Stock Exercise Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.72

'

'

'

'

'

$0.60

'

$0.72

'

'

'

'

Common Stock Exercise Price Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'5 years

'

'

'

'

Derivative, Gain on Derivative

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,022,319

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross cash proceed from private placement

'

'

'

'

0

1,467,500

'

'

'

'

'

'

'

'

'

2,034,664

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Noncash consideration expense

'

'

'

814,500

'

'

'

'

'

'

'

'

'

'

'

3,987,655

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock dividend payable

'

'

'

'

'

'

'

93,361

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Warrants Exercised

'

'

'

'

9,831,414

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

982,300

982,300

'

982,300

'

'

'

'

Warrant Exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

982,300

'

'

'

'

'

'

'

Proceeds Exercise Of Warrants

'

'

'

'

-2,254,999

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

542,229

'

'

'

'

'

'

Increase Decrease In Capital

'

'

'

'

204,513

'

'

'

'

'

'

'

'

'

608,419

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,172,000

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

'

'

10,653,469

12,972,664

'

'

8,668,701

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,678,889

'

'

'

'

'

'

'

'

'

982,300

'

'

Derivative, Fair Value, Net, Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

711,675

'

'

Shares Issued In Debt Conversion

'

'

'

'

'

'

'

'

'

'

161,153

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares Warrant Exercised

1,972,976

'

'

'

'

'

'

'

'

'

'

'

'

360,000

'

'

'

'

'

'

'

'

'

177,300

'

'

'

'

1,101,034

'

'

1,101,034

'

'

'

'

Proceeds from Warrant Exercises

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

607,771

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Warrant Issued

'

'

'

'

555,165

'

'

'

'

'

'

'

'

626,328

'

1,074,670

'

'

'

'

'

'

'

7,712,170

'

'

'

'

671,219

'

'

671,219

'

'

'

'

Estimated FairValue Of Warrants

'

'

353,747

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,622,069

'

'

'

'

Proceeds from Issuance of Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

607,771

'

'

'

'

Fair Value Adjustment of Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

343,079

'

'

'

'

Cashless Exercise Price Of Warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.60

$0.60

'

$0.60

'

'

'

$0.60

$0.60

'

'

'

Cashless Exercise Warrant Shares

'

'

'

'

'

'

416,668

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

339,861

'

147,916

'

'

'

'

'

416,668

'

'

'

Adjustments To Additional Paid In Capital Accrued Dividend Payable

'

'

'

'

93,361

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,666,666

'

'

'

'

Stock Issued During Period, Value, Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

1,000,000

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

0.6

1

'

'

'

'

'

'

0.6

'

'

'

'

'

'

0.6

'

'

'

0.6

0.72

Common Stock Issued, Price Per Share

$1.31

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum Exposure Amount For Contingent Liability

1,183,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Liability, Current

'

'

'

'

290,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Exercise Agreement Expense Paid

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

'

'

'

'

'

160,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

3,238,000

1,710,833

'

'

'

'

'

'

'

1,710,833

416,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Warrants Issued During Period

'

'

1,619,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53,950

203,167

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants, Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,035,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued During Period Value

'

'

'

'

168,402

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liabilities Reversed Current

'

'

'

'

$290,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

MAY_and_NOVEMBER_2012_PRIVATE_1

MAY and NOVEMBER 2012 PRIVATE PLACEMENT (Narrative) (Details) (USD $)	1 Months Ended		12 Months Ended
	Nov. 30, 2012	31-May-12	Dec. 31, 2013	Dec. 31, 2012	Nov. 09, 2012	15-May-12
Subsidiary, Sale of Stock [Line Items]	'	'	'	'	'	'
Preferred stock issued in January 2013 private placement, shares	3,238,000	1,710,833	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	'	1,619,000	1,710,833
Total consideration for common stock	$809,500	$1,026,500	'	'	'	'
Net proceeds from January 2013 preferred stock private placement	681,000	786,500	2,034,664	0	'	'
Conversion of accounts payable	98,500	150,000	'	'	'	'
Forgiveness Of Directors Fees	30,000	'	'	'	'	'
Minority interest in Goodrich Tobacco, percentage	'	'	'	'	'	4.00%
Minority interest in Goodrich Tobacco	'	90,000	'	'	'	'
Warrant exercise price	$1	$1	'	'	'	'
Warrants issued, value	353,747	1,841,000	'	'	'	'
Noncash consideration expense	'	814,500	'	'	'	'
Executive Officer [Member]	'	'	'	'	'	'
Subsidiary, Sale of Stock [Line Items]	'	'	'	'	'	'
Preferred stock issued in January 2013 private placement, shares	1,080,000	44,000	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	'	540,000	'
Total consideration for common stock	270,000	26,400	'	'	'	'
Director [Member]	'	'	'	'	'	'
Subsidiary, Sale of Stock [Line Items]	'	'	'	'	'	'
Preferred stock issued in January 2013 private placement, shares	120,000	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	'	60,000	'
Forgiveness Of Directors Fees	$30,000	'	'	'	'	'

MACHINERY_AND_EQUIPMENT_Narrat

MACHINERY AND EQUIPMENT (Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
			Cigarete Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]	'	'	'
Machinery and Equipment, Gross	$3,220,000	$0	'
Assets Held-for-sale, Current, Total	457,696	0	'
Property, Plant and Equipment, Other, Gross	210,000	0	'
Property, Plant and Equipment, Additions	'	'	$2,762,304

MACHINERY_AND_EQUIPMENT_Detail

MACHINERY AND EQUIPMENT (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Cigarette manufacturing equipment	$3,220,000	$0
Office furniture, fixtures and equipment	17,059	9,106
Leasehold improvements	14,500	0
Deposit for purchase of machine parts and other assets	210,000	0
Property Plant And Equipment Including Assets Held For Sale	3,461,559	9,106
Less: cigarette manufacturing equipment held for resale	457,696	0
Property, Plant and Equipment, Gross, Total	3,003,863	9,106
Less: accumulated depreciation	6,103	3,076
Machinery and equipment, net	$2,997,760	$6,030

DEMAND_BANK_LOAN_Narrative_Det

DEMAND BANK LOAN (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Demand bank loan	$174,925	$174,925
Annual interest rate above prime rate	0.75%	0.75%
Interest rate	4.00%	4.00%
Repayment of outstanding principal amount, period	'30 days	'

NOTES_PAYABLE_Notes_Payable_De

NOTES PAYABLE (Notes Payable) (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jan. 25, 2011

Dec. 31, 2013

Sep. 30, 2013

Jan. 31, 2013

Dec. 31, 2012

Mar. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Apr. 13, 2012

Dec. 31, 2013

Aug. 02, 2013

Jan. 15, 2013

Dec. 31, 2012

Dec. 31, 2013

Jan. 23, 2013

Dec. 31, 2012

Dec. 31, 2013

Jan. 24, 2013

Dec. 31, 2012

Dec. 31, 2013

Feb. 01, 2013

Dec. 31, 2012

Note dated March 31, 2011 [Member]

Note dated March 31, 2011 [Member]

Note dated January 25, 2011 [Member]

Note dated January 25, 2011 [Member]

Note dated January 25, 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 22 2012 and April 13 2012 [Member]

Note Dated March 22 2012 and April 13 2012 [Member]

Note Dated March 22 2012 and April 13 2012 [Member]

Note Dated January 15 2013 [Member]

Note Dated January 15 2013 [Member]

Note Dated January 15 2013 [Member]

Note Dated January 15 2013 [Member]

Note Dated January 23 2013 [Member]

Note Dated January 23 2013 [Member]

Note Dated January 23 2013 [Member]

Note Dated January 24 2013 [Member]

Note Dated January 24 2013 [Member]

Note Dated January 24 2013 [Member]

Note Dated February 1 2013 [Member]

Note Dated February 1 2013 [Member]

Note Dated February 1 2013 [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes payable

$0

$617,000

$0

$77,000

$0

$140,000

$140,000

$0

$175,000

$81,714

$350,000

$350,000

$0

$50,000

$25,000

$0

$136,671

$226,780

$0

$0

$150,000

$0

$0

$58,340

$0

$0

$474,893

$0

NOTES_PAYABLE_Narrative_Detail

NOTES PAYABLE (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Oct. 11, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2013

Dec. 31, 2011

Mar. 31, 2011

31-May-12

Dec. 31, 2012

Oct. 02, 2013

Jul. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 25, 2011

Jan. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Mar. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Apr. 13, 2012

Oct. 02, 2013

Dec. 31, 2013

Aug. 02, 2013

Jan. 15, 2013

Dec. 31, 2012

Jan. 23, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jan. 24, 2013

Dec. 31, 2012

Oct. 02, 2013

Dec. 31, 2013

Feb. 01, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Feb. 06, 2013

Jan. 31, 2013

Aug. 09, 2012

Convertible Note dated March 31, 2011 [Member]

Convertible Note dated March 31, 2011 [Member]

Convertible Note dated March 31, 2011 [Member]

Convertible Note dated March 31, 2011 [Member]

Note dated January 25, 2011 [Member]

Note dated January 25, 2011 [Member]

Note dated January 25, 2011 [Member]

Note dated January 25, 2011 [Member]

Note dated January 25, 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 13 2013 and March 30 2011 [Member]

Note Dated March 22 2012 and April 13 2012 [Member]

Note Dated March 22 2012 and April 13 2012 [Member]

Note Dated March 22 2012 and April 13 2012 [Member]

Note Dated January 15 2013 [Member]

Note Dated January 15 2013 [Member]

Note Dated January 15 2013 [Member]

Note Dated January 15 2013 [Member]

Note Dated January 15 2013 [Member]

Note Dated January 23 2013 [Member]

Note Dated January 23 2013 [Member]

Note Dated January 23 2013 [Member]

Note Dated January 24 2013 [Member]

Note Dated January 24 2013 [Member]

Note Dated January 24 2013 [Member]

Note Dated February 1 2013 [Member]

Note Dated February 1 2013 [Member]

Note Dated February 1 2013 [Member]

Note Dated February 1 2013 [Member]

Note dated March 31, 2011 [Member]

Note dated March 31, 2011 [Member]

New Note [Member]

New Note [Member]

New Note [Member]

Amdendment [Member]

Amdendment [Member]

First, Principal Payment [Member]

First, Principal Payment [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes payable

'

$0

$617,000

'

'

$237,000

'

$77,000

'

'

$0

$140,000

$140,000

$81,714

$0

$175,000

'

$350,000

$350,000

$0

$50,000

$25,000

'

$0

$136,671

$226,780

$0

$150,000

$0

$0

$0

$58,340

$0

'

$0

$474,893

$0

$0

$77,000

'

'

'

Notes payable interest rate

'

'

'

'

'

9.00%

'

'

'

'

'

'

12.00%

'

'

'

'

'

4.00%

'

'

15.00%

'

'

'

8.00%

'

15.00%

'

'

'

15.00%

'

'

'

5.00%

'

'

'

'

5.00%

50.00%

Payments on borrowings

'

1,620,299

41,000

'

50,000

'

10,000

'

'

'

'

'

'

268,286

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

339,250

'

'

Repayment of notes payable with convertible notes

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes issued in exchange for portion of Convertible Notes

'

'

'

'

115,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum Financing Prior To Maturity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

25,582

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts Payable

'

'

'

67,704

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Up Front Payment For Closing In Licensing Agreement Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'sooner if the Company closes an in-licensing agreement in which the Company or a subsidiary receives an up-front payment of at least $1 million.

'

'

'

'

'

'

'

'

'

'

'sooner if the Company closes an in-licensing agreement in which the Company or any affiliate receives an up-front payment of at least $1.5 million.

'

'

'

'

'

'

'

Discharge Of Convertible Notes Held By Lender

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

57,500

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment, Interest

$181,233

'

'

'

'

'

'

'

$155,153

$30,000

'

'

'

'

'

'

'

'

'

'

'

'

$138,469

'

'

'

'

$165,473

'

'

'

'

'

$490,701

'

'

'

'

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18-Oct-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONVERTIBLE_NOTES_Narrative_De

CONVERTIBLE NOTES (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Aug. 31, 2013

Feb. 06, 2013

Nov. 30, 2012

Aug. 31, 2012

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 14, 2011

Aug. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 14, 2011

Dec. 31, 2011

Aug. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Aug. 09, 2012

Feb. 06, 2013

Feb. 06, 2013

Nov. 30, 2012

Jan. 31, 2013

Aug. 09, 2012

Mar. 31, 2011

Dec. 31, 2012

Feb. 06, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 14, 2011

Upon Issuance of August 9, 2012 Notes [Member]

Upon Issuance of August 9, 2012 Notes [Member]

Notes Due Twenty Twelve [Member]

Notes Due Twenty Twelve [Member]

Notes Due Twenty Twelve [Member]

Notes Due 2013 [Member]

Notes Due 2013 [Member]

Notes Due 2013 [Member]

Notes Due 2013 [Member]

New Note Two [Member]

New Note [Member]

New Note [Member]

New Note [Member]

New Note [Member]

New Note [Member]

December 2011 Convertible Note Agreement [Member]

Convertible Debt Issued December 14 2011 [Member]

Convertible Debt Issued December 14 2011 [Member]

Officer [Member]

Officer [Member]

Officer [Member]

Minimum [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of investors

'

'

'

'

'

'

'

'

'

'

'

'

24

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes, face amount

'

$396,750

'

'

'

'

'

'

'

'

'

'

$1,926,250

'

'

'

'

$222,600

'

'

'

'

'

'

'

'

'

'

'

$368,000

Proceeds from issuance of notes

'

'

'

'

'

150,000

56,000

'

'

'

'

1,675,000

'

'

210,000

'

'

'

150,000

57,500

'

'

'

'

1,805,500

'

1,805,500

105,000

86,250

'

Convertible notes payable unamortized, original issue discount

'

'

'

'

'

'

'

'

'

'

'

'

251,250

'

'

'

'

12,600

'

'

'

'

'

'

'

'

'

'

'

'

Note maturity date

'

'

'

'

'

'

'

'

'

'

'

14-Dec-12

'

'

9-Aug-13

'

'

'

1-Oct-13

'

'

'

'

'

14-Apr-13

'

'

'

'

'

Convertible notes conversion price per share

$1

'

'

'

'

'

'

'

'

'

'

'

$0.75

'

'

'

'

$0.60

'

'

'

'

'

'

'

'

'

'

'

'

Warrants as percentage of number of shares of common stock converted

'

'

'

'

'

'

'

'

'

'

'

'

120.00%

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, expiration period

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'5 years

'5 years

'

'

'

'5 years

'5 years

'

'

'

'

Warrants, exercise price

'

'

1

'

'

'

'

'

'

'

0.96

'

1.5

'

'

'

'

1

'

1.5

'

'

'

1.5

1.5

'

'

'

'

'

Shares of common stock that would cause note holders additional rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

219,909

'

'

'

'

'

Common stock, closing price

'

'

'

'

'

'

'

'

$0.90

'

'

'

'

'

'

'

'

$0.45

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, beneficial conversion feature

'

'

'

'

'

'

116,600

'

'

'

'

'

'

1,062,758

116,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible note, face amount

'

'

'

'

'

'

120,750

'

'

'

'

'

'

'

'

'

'

'

'

219,909

'

'

'

'

1,523,750

'

'

'

'

'

Common stock issued for short term unsecured notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

215,000

'

'

Debt instrument carrying value, net of unamortized discount

222,600

'

'

'

'

'

55,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock issued per convertible notes

371,000

'

'

'

'

'

161,494

'

'

'

'

'

'

'

'

'

'

'

'

2,035,720

'

'

'

'

'

'

'

'

115,000

'

Warrants issued to purchase common stock

371,000

'

'

371,000

'

'

193,793

'

'

'

'

'

'

'

'

'

'

'

'

2,662,769

'

'

'

'

'

'

'

'

138,000

'

Unamortized discount on convertible notes

'

'

'

'

'

'

66,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant liability

'

'

'

'

'

1,445,091

152,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest due to debt conversion

'

'

'

'

'

17,386

31,000

17,386

'

509,062

509,062

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant liability

'

'

'

'

'

3,779,522

4,173,140

550,000

'

'

731,662

'

'

'

'

'

'

92,750

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of convertible debt discount

'

'

'

'

'

'

1,284,363

'

'

'

'

'

'

'

'

134,296

87,654

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

50.00%

'

15.00%

'

'

'

'

12.00%

Original debt amount

'

'

98,500

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,408,750

'

'

'

'

'

'

'

'

'

'

Payments on borrowings - notes payable

'

'

'

'

'

1,620,299

41,000

'

'

'

'

'

'

'

'

'

'

'

'

339,250

'

'

'

'

'

'

'

'

'

'

Note One Discharged

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$247,250

'

'

'

'

'

'

'

'

'

'

CONVERTIBLE_NOTES_Summary_of_N

CONVERTIBLE NOTES (Summary of Notes and Related Discount) (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 14, 2011

Dec. 31, 2013

Dec. 31, 2012

Aug. 09, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Notes Due 2012 [Member]

Notes Due 2012 [Member]

Notes Due 2012 [Member]

Notes Due 2013 [Member]

Notes Due 2013 [Member]

Notes Due 2013 [Member]

Discount On Loan [Member]

Discount On Loan [Member]

Discount Related to BCF [Member]

Discount Related to BCF [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Face value of all convertible notes payable through maturity

$0

$2,028,100

'

'

'

'

'

'

'

'

'

'

Less unamortized discount

'

'

'

'

251,250

'

'

12,600

0

-63,787

0

-70,509

Convertible Notes, net of unamortized debt discount

0

1,893,804

'

'

'

'

'

'

'

'

'

'

Convertible notes, net of unamortized discount

'

'

$0

$1,805,500

'

$0

$88,304

'

'

'

'

'

DUE_FROM_OR_TO_RELATED_PARTY_N

DUE FROM OR TO RELATED PARTY (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]	'	'	'
Trademark acquired, purchase price	$22,500	'	'
Due from related party	'	$42,069	$36,969

WARRANT_EXCHANGE_PROGRAM_AND_W2

WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Narrative) (Details) (USD $)

1 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

9 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Aug. 31, 2013

Feb. 06, 2013

Nov. 30, 2012

Aug. 31, 2012

31-May-12

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 06, 2013

Dec. 12, 2013

Dec. 12, 2013

Dec. 31, 2013

Dec. 12, 2013

Dec. 31, 2013

Jun. 07, 2013

Sep. 30, 2013

Aug. 31, 2013

Aug. 31, 2012

Dec. 31, 2013

Aug. 09, 2012

Aug. 31, 2012

Dec. 31, 2013

Feb. 06, 2013

Nov. 30, 2012

Dec. 31, 2013

Mar. 31, 2011

Sep. 30, 2013

Nov. 30, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

31-May-12

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Sep. 20, 2013

Aug. 31, 2013

Aug. 06, 2013

Feb. 06, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Aug. 31, 2013

Dec. 31, 2013

Aug. 06, 2013

Jun. 30, 2013

Dec. 31, 2013

Chardan Capital Markets, LLC [Member]

Warrant Exchange Program [Member]

Warrant Exchange Program [Member]

Warrant Exchange Program [Member]

Series Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Upon Issuance of August 9, 2012 Notes [Member]

Upon Issuance of August 9, 2012 Notes [Member]

New Note [Member]

New Note [Member]

New Note [Member]

New Note [Member]

Private Placement And Merger [Member]

Private Placement [Member]

Private Placement [Member]

Warrant One [Member]

Warrant One [Member]

Warrant One [Member]

Warrant One [Member]

Warrant Two [Member]

Warrant Two [Member]

Warrant Two [Member]

Warrant Three [Member]

Warrant Three [Member]

Warrant Three [Member]

Warrant Four [Member]

Series A Warrant [Member]

Series A Warrant [Member]

Series A Warrant [Member]

Series A Warrant [Member]

Series A Warrant [Member]

Series B Warrant [Member]

Series B Warrant [Member]

Series B Warrant [Member]

Series C Warrant [Member]

Series C Warrant [Member]

Series C Warrant [Member]

Series C Warrant [Member]

Series A-1 Preferred Stock [Member]

Chardan Capital Markets, LLC [Member]

Warrant Exchange Program [Member]

Private Placement Debt Due May 2012

Private Placement Debt Due May 2012

Notes Due 2013 [Member]

Notes Due 2013 [Member]

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

371,000

'

'

371,000

'

'

'

193,793

'

'

'

'

'

'

'

'

'

'

371,000

'

'

'

'

2,662,769

'

'

'

'

'

'

3,455,039

5,482,055

124,217

'

'

3,062,665

'

110,336

'

193,200

374,007

'

'

'

'

'

'

'

3,947,232

'

'

'

'

'

Warrants, exercise price

'

'

1

'

'

'

'

'

'

'

'

'

1.38

'

'

'

'

'

'

0.6

1

'

0.96

1.5

'

'

1.5

'

'

'

2.21

2.73

1

'

'

1.96

1.39

1.2

'

1.5

1.27

0.6

'

'

'

'

'

'

'

0.6

'

'

'

'

Warrants outstanding upon conversion of convertible notes

'

'

'

'

'

'

10,653,469

12,972,664

8,668,701

'

'

6,732,088

'

'

'

'

19,616,308

'

'

'

'

'

184,047

'

'

'

'

'

'

'

'

'

'

'

'

'

'

180,047

'

'

802,215

3,678,889

'

'

'

'

'

'

'

'

'

'

982,300

'

Warrant liability - net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,022,319

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$152,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, expiration period

'5 years

'5 years

'5 years

'5 years

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

Issuance of warrants as derivative liability instruments upon conversion of note payable

'

'

'

'

'

'

3,779,522

4,173,140

550,000

'

'

'

'

'

'

'

'

731,662

92,750

'

'

'

731,662

'

'

'

'

'

'

'

'

'

1,841,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,022,319

Warrants issued during the period,

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,710,833

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Original debt amount

'

'

98,500

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,408,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock issued per convertible notes

371,000

'

'

'

'

'

'

161,494

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,035,720

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible note, face amount

'

'

'

'

'

'

'

120,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

219,909

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,250,000

4,166,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Additional Conversion Price

'

'

'

'

'

'

4,166,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,166,666

'

'

'

'

'

2,083,334

'

'

2,083,334

'

'

'

Warrant Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.60

'

'

'

'

$0.60

'

$1.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, Fair Value, Net, Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

711,675

'

Number Of Warrants Exercised

'

'

'

'

'

'

9,831,414

0

'

'

'

-513,949

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,518,600

'

'

'

'

'

'

'

'

'

'

'

982,300

982,300

'

'

982,300

'

'

'

Exercise Of Warrants Upon Conversion Of Equity On Cashless Basis

'

'

'

'

'

1,160,080

1,160,080

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Warrant Issued

'

'

'

'

'

'

555,165

'

'

'

'

'

'

'

'

'

'

626,328

'

1,074,670

'

'

'

'

'

7,637,813

'

482,654

'

'

421,817

'

'

3,013,587

111,468

3,661,718

'

'

158,919

'

'

7,712,170

'

'

'

'

671,219

'

'

'

671,219

'

'

'

Warrant Liabilities Fair Value

'

'

'

'

'

'

1,445,091

152,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Of Warrants For Cash

'

'

'

'

'

275,000

275,000

'

'

'

'

'

'

'

'

'

'

'

'

974,201

'

'

'

'

'

'

'

'

'

'

165,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless Exercise Warrant Shares

'

'

'

'

'

'

'

'

'

416,668

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

63,000

'

'

'

'

'

'

'

339,861

'

147,916

'

'

'

'

'

'

416,668

'

'

Conversion Price

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,666,666

'

'

'

Stock Issued During Period, Value, Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

1,000,000

'

'

'

Other Nonoperating Income (Expense), Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,330,734

'

'

'

Proceeds from Issuance of Preferred Stock and Preference Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,987,655

Cashless Exercise Price Of Warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.60

$0.60

'

$0.60

'

'

'

'

$0.60

$0.60

'

'

Interest Expense, Debt

'

'

'

'

'

'

17,386

31,000

17,386

'

'

'

'

'

'

'

'

'

'

'

'

509,062

509,062

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

185,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Warrants Issued During Period

'

'

1,619,000

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53,950

203,167

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated FairValue Of Warrants

'

'

353,747

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,622,069

'

'

'

Stock Issued During Period Shares Warrant Exercised

1,972,976

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

360,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

177,300

'

'

'

'

1,101,034

'

'

'

1,101,034

'

'

'

Change In Fair Value Of Warrant Liabilities

'

'

'

'

'

'

19,271,977

1,183,543

'

'

'

'

'

'

'

'

'

'

'

19,271,977

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Exercise Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.72

'

'

'

'

'

$0.60

'

'

$0.72

'

'

'

Proceeds from Issuance of Warrants

'

'

'

'

'

'

'

'

'

'

'

3,559,763

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

607,771

'

'

'

Issuance Of Shares Under Warrant Exchange Program

'

'

'

'

'

'

'

'

'

'

'

5,348,172

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Right Issued

'

'

'

'

'

'

11,570,274

3,523,033

'

'

'

156,197

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Warrants Exercised

'

'

'

'

'

'

-9,831,414

0

'

'

'

513,949

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,518,600

'

'

'

'

'

'

'

'

'

'

'

-982,300

-982,300

'

'

-982,300

'

'

'

Common Stock Warrants Issued Additional Number

'

'

'

'

'

'

1,665,400

780,930

'

'

'

138,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Exchange Inducement Expense

'

'

'

'

'

'

3,736,313

0

'

'

'

3,736,313

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Businesses, Gross

'

'

'

'

'

'

200,000

'

'

'

'

320,378

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance Of Common Stock Value In Payments Of Financing Cost

'

'

'

'

'

'

'

'

'

'

'

'

'

462,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Warrants Issued Number

'

'

'

'

'

'

'

'

'

'

'

3,437,072

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Adjustment of Warrants

'

'

'

'

'

'

'

'

'

'

'

'

$4,612,263

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$343,079

'

'

'

WARRANT_EXCHANGE_PROGRAM_AND_W3

WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Roll-Forward of Warrant Liabilitiy from Initial Valuation) (Details) (USD $)

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Aug. 31, 2013

Aug. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Warrant [Member]

Warrant [Member]

Warrant [Member]

Upon partial conversion of December 14, 2011 Notes [Member]

Upon issuance - May 15, 2012 [Member]

Upon maturity of August 9, 2012 Notes [Member]

Upon issuance November 9, 2012 [Member]

Upon issuance Q1 2013 [Member]

Upon issuance Q2 2013 [Member]

Upon issuance Q3 2013 [Member]

Upon Conversion of August 9, 2012 Notes [Member]

Upon Exercise Price of Series A and Series C Warrants [Member]

Upon Exercise of Warrants Q2 2013 [Member]

Upon Exercise of Warrants Q3 2013 [Member]

Warrant [Member]

Warrant [Member]

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant liability, beginning balance

$4,173,140

$550,000

'

$731,662

$92,750

$152,100

$1,841,000

$92,750

$353,747

$6,022,319

$711,675

$1,622,069

$731,662

$626,328

'

'

Reclassification of warrant liability to equity upon exercise of warrants

14,433,178

0

'

'

'

'

'

'

'

'

'

'

'

'

-204,513

-6,542,904

Reclassification Of Warrant Liability To Equity Upon Exercise Of Warrants

-7,712,170

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of inducement from Warrant Exchange Program - Q4 2013

3,274,313

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification Of Warrant Liability To Equity Resulting From Warrant Exchange Program

-19,639,465

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss (Gain) as a result of change in fair value

19,271,977

1,183,543

19,271,977

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value, ending balance

$3,779,522

$4,173,140

'

$731,662

$92,750

$152,100

$1,841,000

$92,750

$353,747

$6,022,319

$711,675

$1,622,069

$731,662

$626,328

'

'

WARRANT_EXCHANGE_PROGRAM_AND_W4

WARRANT EXCHANGE PROGRAM AND WARRANTS FOR COMMON STOCK (Warrant Activity) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]	'	'
Warrant outstanding beginning balance	12,972,664	8,668,701
Warrants issued	11,570,274	3,523,033
warrants issued as part of Warrant Exchange Program	138,666	'
Additional warrants due to anti-dilution provisions	1,665,400	780,930
Warrants exercised	-9,831,414	0
Warrants exercised as part of Warrant Exchange Program	-5,862,121	'
Warrant outstanding and exercisable ending balance	10,653,469	12,972,664
Composition of outstanding warrants:	'	'
Warrants containing anti-dilution feature	3,921,381	'
Warrants with anti-dilution feature removed	6,732,088	'
Warrant outstanding and exercisable ending balance	10,653,469	12,972,664

RETIREMENT_PLAN_Narrative_Deta

RETIREMENT PLAN (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]	'
Defined Benefit Plan, Funded Percentage	3.00%
Defined Benefit Plan, Contributions by Employer	$34,873

COMMITMENTS_Narrative_Details

COMMITMENTS (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Commitments [Line Items]	'	'
Milestone payment upon approval of a product	$150,000	'
Patent cost and patent maintenance	101,902	104,558
Lease agreements, annual license fees	75,000	'
Leased office space, lease term	'3 years	'
Business Combination, Consideration Transferred, Total	1,000,000	'
Payments to Acquire Businesses, Gross	200,000	'
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	800,000	'
Capital Leases, Future Minimum Payments Due, Next Twelve Months	96,000	'
Capital Leases, Future Minimum Payments Due in Two Years	123,000	'
Capital Leases, Future Minimum Payments Due in Three Years	298,275	'
Capital Leases, Future Minimum Payments Due in Four Years	338,250	'
Capital Leases, Future Minimum Payments Due in Five Years	338,250	'
License Agreements, Expiration Date	'2022	'
Minimum [Member]	'	'
Commitments [Line Items]	'	'
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	640,000	'
Maximum [Member]	'	'
Commitments [Line Items]	'	'
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	1,066,667	'
Fiscal Year 2013 [Member]	'	'
Commitments [Line Items]	'	'
Annual minimum royalty payments	75,000	'
Fiscal Year 2016 [Member]	'	'
Commitments [Line Items]	'	'
Annual minimum royalty payments	$225,000	'

COMMITMENTS_Schedule_Rent_Deta

COMMITMENTS (Schedule Rent) (Details) (USD $)	Dec. 31, 2013
Operating Leased Assets [Line Items]	'
2014	$45,000
2015	$10,000

EARNINGS_PER_COMMON_SHARE_Comp

EARNINGS PER COMMON SHARE (Computation of Basic and Diluted Earnings Per Common Share) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Net loss attributed to common shareholders	($26,153,158)	($6,735,281)
Denominator for basic earnings per share-weighted average shares outstanding (in shares)	43,635,182	30,419,556
Effect of dilutive securities:	'	'
Warrants, restricted stock and options outstanding (in shares)	0	0
Denominator for diluted earnings per common share - weighted average shares adjusted for dilutive securities (in shares)	43,635,182	30,419,556
Loss per common share - basic	($0.60)	($0.22)
Loss per common share- diluted	($0.60)	($0.22)

EARNINGS_PER_COMMON_SHARE_Anti

EARNINGS PER COMMON SHARE (Anti-Dilutive Securities Outstanding Excluded from Computation) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities outstanding but excluded from computation of earnings per share	11,813,469	19,436,446
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities outstanding but excluded from computation of earnings per share	10,653,469	12,972,664
Convertible Debt Issued December 14 2011 [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities outstanding but excluded from computation of earnings per share	0	4,706,782
Shares issued in debt conversion	3,061,034	'
Convertible Debt Issued August 9, 2012 [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities outstanding but excluded from computation of earnings per share	0	742,000
Shares issued in debt conversion	371,000	'
Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities outstanding but excluded from computation of earnings per share	500,000	550,000
Options Held [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities outstanding but excluded from computation of earnings per share	660,000	465,000

STOCK_BASED_COMPENSATION_Narra

STOCK BASED COMPENSATION (Narrative) (Details) (USD $)	12 Months Ended								1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Oct. 21, 2010	Apr. 30, 2013
				Grant Date On April 1 2013 [Member]	Third Party [Member]	Equity Incentive Plan 2010 [Member]	Equity Incentive Plan 2010 [Member]	Equity Incentive Plan 2010 [Member]	Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Shares authorized for grant under EIP	'	'	'	'	'	'	'	4,250,000	'
Equity based employee compensation expense	$980,162	$807,675	'	'	'	$998,214	$732,209	'	'
Restricted shares awarded vested immediately	'	'	'	100,000	'	890,000	'	'	'
Unrecognized compensation expense related to non-vested restricted shares and stock option	100,000	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$0.68	$0.56	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	186,959	'	242,160	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	'	'	'	'	'	'	'	'	150,000
Stock Issued During Period, Shares, Issued for Services	1,780,000	'	'	'	'	'	'	'	'
Stock Issued During Period, Value, Issued for Services	'	10,000	'	'	1,363,748	'	'	'	'
Proceeds from Stock Options Exercised	$5,200	$0	'	'	'	'	'	'	'
Exercised	20,000	'	'	'	'	'	'	'	'

STOCK_BASED_COMPENSATION_Sched

STOCK BASED COMPENSATION (Schedule of Fair Value Assumptions) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Risk-free interest rate	1.89%	1.71%
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	90.00%	90.00%
Expected life of options	'10 years	'10 years

STOCK_BASED_COMPENSATION_Summa

STOCK BASED COMPENSATION (Summary of All Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Number of Options	'	'
Options Outstanding, Beginning of Period	465,000	35,000
Granted	215,000	455,000
Forfeited	'	-25,000
Exercised	-20,000	'
Options Outstanding, End of Period	660,000	465,000
Exercisable, End of Period	660,000	'
Weighted Average Exercise Price	'	'
Options Outstanding, Beginning of Period	$0.69	$1.20
Granted	$0.80	$0.65
Forfeited	'	$0.69
Exercised	$0.26	'
Options Outstanding, End of Period	$0.74	$0.69
Exercisable, End of Period	$0.74	'
Weighted Average Remaining Contractual Term	'	'
Options Outstanding, End of Period	'8 years 7 months 6 days	'
Exercisable, End of Period	'8 years 7 months 6 days	'
Aggregate Intrinsic Value	'	'
Options Outstanding, End of Period	$923,500	'
Exercisable at December 31, 2013	$923,500	'

INCOME_TAXES_Schedule_of_Provi

INCOME TAXES (Schedule of Provision (Benefit) for Income Taxes) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Current:	'	'
Federal	$0	$0
State	0	0
Total current	0	0
Deferred:	'	'
Federal	829,306	-1,370,382
State	186,414	-308,039
Total deferred	1,015,720	-1,678,421
Change in valuation allowance	-1,015,720	1,678,421
Total income tax provision (benefit)	$0	$0

INCOME_TAXES_Schedule_of_statu

INCOME TAXES (Schedule of statutory federal rate to pre-tax accounting loss) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Statutory federal rate	-34.00%	-34.00%
Permanent items	1.80%	2.00%
Derivative liability	35.50%	10.10%
State tax provision, net of federal benefit	0.50%	-3.00%
Valuation allowance	-3.90%	24.90%
Effective tax rate (benefit) provision	0.00%	0.00%

INCOME_TAXES_Schedule_of_Defer

INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carryforwards	$2,616,624	$3,694,817
Derivative liability	21,725	21,725
Inventory reserve	19,584	69,120
Stock-based compensation	131,450	0
Other	1,292	967
Total deferred tax assets	2,790,675	3,776,629
Deferred tax liabilities:	'	'
Inventory	-52,445	0
Fixed assets	-2,956	-2,333
Patents and trademarks	-523,157	-490,882
Stock-based compensation	0	-28,300
Beneficial conversion feature of convertible debt	0	-27,277
Total deferred tax liabilities	-578,558	-548,792
Valuation allowance	-2,212,117	-3,227,837
Net deferred taxes	$0	$0

INCOME_TAXES_Narrative_Details

INCOME TAXES (Narrative) (Details) (USD $)	Dec. 31, 2013
Net operating loss carry forwards	$6,800,000

SUBSEQUENT_EVENTS_Narrrative_D

SUBSEQUENT EVENTS (Narrrative) (Details) (Subsequent Event [Member], Restricted Stock [Member])	1 Months Ended
	Jan. 27, 2014
Subsequent Event [Member] | Restricted Stock [Member]	'
Class of Stock [Line Items]	'
Stock Issued During Period, Shares, Share-based Compensation, Gross	850,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'1 year